<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1352" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1352/" /><meta name="ncbi_pagename" content="Spinal Muscular Atrophy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Spinal Muscular Atrophy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Spinal Muscular Atrophy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/11/14" /><meta name="citation_author" content="Thomas W Prior" /><meta name="citation_author" content="Meganne E Leach" /><meta name="citation_author" content="Erika Finanger" /><meta name="citation_pmid" content="20301526" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1352/" /><meta name="citation_keywords" content="SMA" /><meta name="citation_keywords" content="Spinal Muscular Atrophy I" /><meta name="citation_keywords" content="Spinal Muscular Atrophy II" /><meta name="citation_keywords" content="Spinal Muscular Atrophy 0" /><meta name="citation_keywords" content="Spinal Muscular Atrophy III" /><meta name="citation_keywords" content="Spinal Muscular Atrophy IV" /><meta name="citation_keywords" content="Survival motor neuron protein" /><meta name="citation_keywords" content="SMN1" /><meta name="citation_keywords" content="SMN2" /><meta name="citation_keywords" content="Spinal Muscular Atrophy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Spinal Muscular Atrophy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Thomas W Prior" /><meta name="DC.Contributor" content="Meganne E Leach" /><meta name="DC.Contributor" content="Erika Finanger" /><meta name="DC.Date" content="2019/11/14" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1352/" /><meta name="description" content="Spinal muscular atrophy (SMA) is characterized by muscle weakness and atrophy resulting from progressive degeneration and irreversible loss of the anterior horn cells in the spinal cord (i.e., lower motor neurons) and the brain stem nuclei. The onset of weakness ranges from before birth to adulthood. The weakness is symmetric, proximal &gt; distal, and progressive. Before the genetic basis of SMA was understood, it was classified into clinical subtypes based on maximum motor function achieved; however, it is now apparent that the phenotype of SMN1-associated SMA spans a continuum without clear delineation of subtypes. With supportive care only, poor weight gain with growth failure, restrictive lung disease, scoliosis, and joint contractures are common complications; however, newly available targeted treatment options are changing the natural history of this disease." /><meta name="og:title" content="Spinal Muscular Atrophy" /><meta name="og:type" content="book" /><meta name="og:description" content="Spinal muscular atrophy (SMA) is characterized by muscle weakness and atrophy resulting from progressive degeneration and irreversible loss of the anterior horn cells in the spinal cord (i.e., lower motor neurons) and the brain stem nuclei. The onset of weakness ranges from before birth to adulthood. The weakness is symmetric, proximal &gt; distal, and progressive. Before the genetic basis of SMA was understood, it was classified into clinical subtypes based on maximum motor function achieved; however, it is now apparent that the phenotype of SMN1-associated SMA spans a continuum without clear delineation of subtypes. With supportive care only, poor weight gain with growth failure, restrictive lung disease, scoliosis, and joint contractures are common complications; however, newly available targeted treatment options are changing the natural history of this disease." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1352/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/sma/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1352/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE888D43DFC8982100000000013B0090.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1352_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1352_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/kennedy/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sma-xli/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1352_"><span class="title" itemprop="name">Spinal Muscular Atrophy</span></h1><p class="contrib-group"><span itemprop="author">Thomas W Prior</span>, PhD, FACMG, <span itemprop="author">Meganne E Leach</span>, MSN, PNP, and <span itemprop="author">Erika Finanger</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1352_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1352_ai__"><div class="contrib half_rhythm"><span itemprop="author">Thomas W Prior</span>, PhD, FACMG<div class="affiliation small">Center for Human Genetics Laboratory<br />UH Cleveland Medical Center<br />Case Western Reserve University<br />Cleveland, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.slatipsohhu@roirp.samoht" class="oemail">gro.slatipsohhu@roirp.samoht</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Meganne E Leach</span>, MSN, PNP<div class="affiliation small">Division of Neurology and Pediatrics<br />Oregon Health and Science University<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usho@mhcael" class="oemail">ude.usho@mhcael</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Erika Finanger</span>, MD<div class="affiliation small">Division of Neurology and Pediatrics<br />Oregon Health and Science University<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usho@regnanif" class="oemail">ude.usho@regnanif</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 24, 2000</span>; Last Update: <span itemprop="dateModified">November 14, 2019</span>.</p><p><em>Estimated reading time: 39 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="sma.Summary" itemprop="description"><h2 id="_sma_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Spinal muscular atrophy (SMA) is characterized by muscle weakness and atrophy resulting from progressive degeneration and irreversible loss of the anterior horn cells in the spinal cord (i.e., lower motor neurons) and the brain stem nuclei. The onset of weakness ranges from before birth to adulthood. The weakness is symmetric, proximal &#x0003e; distal, and progressive. Before the genetic basis of SMA was understood, it was classified into clinical subtypes based on maximum motor function achieved; however, it is now apparent that the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of <i>SMN1</i>-associated SMA spans a continuum without clear delineation of subtypes. With supportive care only, poor weight gain with growth failure, restrictive lung disease, scoliosis, and joint contractures are common complications; however, newly available targeted treatment options are changing the natural history of this disease.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of SMA is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a history of motor difficulties or regression, proximal muscle weakness, reduced/absent deep tendon reflexes, evidence of motor unit disease, AND/OR by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SMN1</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. Increases in <i>SMN2</i> copy number often modify the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Therapies targeted to the underlying disease mechanism include nusinersen (Spinraza<sup>&#x000ae;</sup>; an antisense oligonucleotide) for the treatment of all types of SMA and onasemnogene abeparvovec-xioi (Zolgensma<sup>&#x000ae;</sup>; <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> replacement therapy) for the treatment of type I SMA. These targeted treatments may prevent the development or slow the progression of some features of SMA; efficacy is improved when treatment is initiated before symptom onset. It is unclear what the long-term effect of these treatments will be or if new phenotypes will arise in treated individuals.</p><p>Proactive supportive treatment by a multidisciplinary team is essential to reduce symptom severity, particularly in the most severe cases of SMA. When nutrition or dysphagia is a concern, placement of a gastrostomy tube early in the course of the disease is appropriate. Standard therapy for gastroesophageal reflux disease and chronic constipation. Formal consultation and frequent follow up with a pulmonologist familiar with SMA is necessary. As respiratory function deteriorates, tracheotomy or noninvasive respiratory support may be offered. Surgical repair for scoliosis should be considered based on progression of the curvature, pulmonary function, and bone maturity. Surgical intervention for hip dislocation for those with pain.</p><p><i>Surveillance:</i> Presymptomatic individuals require monitoring for the development of symptoms to determine appropriate timing to initiate targeted and/or supportive therapies. Multidisciplinary evaluation every six months or more frequently for weaker children is indicated to assess nutritional state, respiratory function, motor function, and orthopedic status, and to determine appropriate interventions.</p><p><i>Agents/circumstances to avoid:</i> Prolonged fasting, particularly in the acutely ill infant with SMA.</p><p><i>Evaluation of relatives at risk:</i> It is appropriate to determine the genetic status of younger, apparently asymptomatic sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from prompt initiation of targeted treatment.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>SMA is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. Each pregnancy of a couple who have had a child with SMA has an approximately 25% chance of producing an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child, an approximately 50% chance of producing an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and an approximately 25% chance of producing an unaffected child who is not a carrier. These recurrence risks deviate slightly from the norm for autosomal recessive inheritance because about 2% of affected individuals have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>SMN1</i> variant on one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>; in these instances, only one parent is a carrier of an <i>SMN1</i> variant, and thus the sibs are not at increased risk for SMA. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the diagnosis of SMA has been confirmed by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> in an affected family member.</p></div></div><div id="sma.GeneReview_Scope"><h2 id="_sma_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="sma.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1352/table/sma.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sma.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sma.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spinal Muscular Atrophy: Included Phenotypes</th></tr></thead><tbody><tr><td headers="hd_h_sma.Td_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Spinal muscular atrophy 0</div></li><li class="half_rhythm"><div>Spinal muscular atrophy I</div></li><li class="half_rhythm"><div>Spinal muscular atrophy II</div></li><li class="half_rhythm"><div>Spinal muscular atrophy III</div></li><li class="half_rhythm"><div>Spinal muscular atrophy IV</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#sma.Nomenclature">Nomenclature</a>.</p></div></dd></dl></div></div></div><p>Note: This review is restricted to the discussion of <i>SMN1</i>-related spinal muscular atrophy. For other genetic causes of the spinal muscular atrophy <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, see <a href="#sma.Differential_Diagnosis">Differential Diagnosis</a>.</p></div><div id="sma.Diagnosis"><h2 id="_sma_Diagnosis_">Diagnosis</h2><p>A consensus document on the diagnosis of children with SMA was initially developed by <a class="bk_pop" href="#sma.REF.wang.2007.1027">Wang et al [2007]</a> and was updated by <a class="bk_pop" href="#sma.REF.mercuri.2018.103">Mercuri et al [2018]</a> (see <a href="#sma.Establishing_the_Diagnosis">Establishing the Diagnosis</a>).</p><div id="sma.Suggestive_Findings"><h3>Suggestive Findings</h3><p><b>Scenario 1. Abnormal <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> (NBS) result</b></p><ul><li class="half_rhythm"><div>NBS for spinal muscular atrophy (SMA) is primarily based on real-time <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> that detects the common <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> and may also detect <i>SMN2</i> copy number on dried blood spots [<a class="bk_pop" href="#sma.REF.chien.2017.124">Chien et al 2017</a>].</div></li><li class="half_rhythm"><div>Follow-up <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> confirmation of a positive NBS result is recommended (see <a href="#sma.Establishing_the_Diagnosis">Establishing the Diagnosis</a>).</div></li></ul><p><b>Scenario 2. Symptomatic individual</b> who has EITHER atypical findings associated with later-onset SMA OR infantile-onset SMA that has not been treated (either because NBS was not performed or because it yielded a false negative result)</p><ul><li class="half_rhythm"><div>History of motor difficulties, especially with loss of skills</div></li><li class="half_rhythm"><div>Proximal &#x0003e; distal muscle weakness</div></li><li class="half_rhythm"><div>Hypotonia</div></li><li class="half_rhythm"><div>Areflexia/hyporeflexia</div></li><li class="half_rhythm"><div>Tongue fasciculations</div></li><li class="half_rhythm"><div>Hand tremor</div></li><li class="half_rhythm"><div>Recurrent lower respiratory tract infections or severe bronchiolitis in the first few months of life</div></li><li class="half_rhythm"><div>Evidence of motor unit disease on electromyogram</div></li></ul></div><div id="sma.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of SMA <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a history of motor difficulties or regression, proximal muscle weakness, reduced/absent deep tendon reflexes, and evidence of motor unit disease; AND/OR by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SMN1</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1352/table/sma.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figsmaTmoleculargenetictestingusedin" rid-ob="figobsmaTmoleculargenetictestingusedin">Table 1</a>). Increases in <i>SMN2</i> copy number often modify the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><div id="sma.Molecular_Genetic_Testing_Approaches"><h4>Molecular Genetic Testing Approaches</h4><p><b>Scenario 1. Abnormal <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> (NBS) result</b></p><p>When NBS results suggest the diagnosis of SMA, confirmatory <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> typically includes <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>. Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to determine the dosage of <i>SMN1</i> is performed first for the <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7. If one copy of <i>SMN1</i> exon 7 is present<i>,</i> perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>SMN1</i>. If exon 7 is present in both copies of <i>SMN1</i>, consider other diagnoses (see <a href="#sma.Differential_Diagnosis">Differential Diagnosis</a>).</p><p>Because <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> cannot determine whether a putative <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> variant is in <i>SMN1</i> or <i>SMN2</i> (see <a href="#sma.Molecular_Genetics">Molecular Genetics</a>), one of the following is required to confirm that the variant is present in <i>SMN1</i>:</p><ul><li class="half_rhythm"><div>Establish that the <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> variant has previously been reported in <i>SMN1</i>; OR</div></li><li class="half_rhythm"><div>Sequence a long-range <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> product or a subclone of <i>SMN1</i>.</div></li></ul><p>Note: Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to determine <i>SMN2</i> copy number can be performed to provide additional information for clinical correlation if the diagnosis of SMA is confirmed on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a href="#sma.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>).</p><p>See <a class="figpopup" href="/books/NBK1352/figure/sma.F1/?report=objectonly" target="object" rid-figpopup="figsmaF1" rid-ob="figobsmaF1">Figure 1</a> for a summary of the diagnostic algorithm for SMA as published by <a class="bk_pop" href="#sma.REF.mercuri.2018.103">Mercuri et al [2018]</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figsmaF1" co-legend-rid="figlgndsmaF1"><a href="/books/NBK1352/figure/sma.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figsmaF1" rid-ob="figobsmaF1"><img class="small-thumb" src="/books/NBK1352/bin/sma-Image001.gif" src-large="/books/NBK1352/bin/sma-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndsmaF1"><h4 id="sma.F1"><a href="/books/NBK1352/figure/sma.F1/?report=objectonly" target="object" rid-ob="figobsmaF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Diagnostic algorithm for SMA </p></div></div><p><b>Scenario 2. A symptomatic individual</b> who has findings associated with later-onset SMA or untreated infantile-onset SMA (resulting from NBS not performed or false negative NBS result).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> (see above) or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>SMN1</i>, <i>SMN2</i>, and other genes of interest (see <a href="#sma.Differential_Diagnosis">Differential Diagnosis</a>). Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK1352/table/sma.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figsmaTmoleculargenetictestingusedin" rid-ob="figobsmaTmoleculargenetictestingusedin">Table 1</a>).</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><div id="sma.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Spinal Muscular Atrophy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1352/table/sma.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sma.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Type of Testing</th><th id="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_3" style="text-align:left;vertical-align:middle;">Proportion of<br />SMA Attributed<br />to Pathogenic<br />Variants in Gene</th><th id="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup><br />Detectable by Method</th></tr><tr><th headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_4" id="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></th><th headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_4" id="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<br /><a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>4</sup></th></tr></thead><tbody><tr><td headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Diagnostic, <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, prenatal</td><td headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SMN1</i></td><td headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%</td><td headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_sma.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%-5%&#x000a0;<sup>5</sup></td><td headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_sma.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">95%-98%&#x000a0;<sup>6,&#x000a0;7</sup></td></tr><tr><td headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Prognostic</td><td headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SMN2</i></td><td headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_sma.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_sma.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_sma.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 8</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="sma.TF.1.1"><p class="no_margin">See <a href="/books/NBK1352/#sma.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="sma.TF.1.2"><p class="no_margin">See <a href="#sma.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="sma.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="sma.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a> and multiplex ligation-dependent probe amplification (MLPA) to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications. Note that <i>SMN1</i> and <i>SMN2</i> are nearly identical; therefore, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray cannot be used to determine <i>SMN1</i> and <i>SMN2</i> copy number.</p></div></dd><dt>5. </dt><dd><div id="sma.TF.1.5"><p class="no_margin">Detects the 2%-5% of individuals who are <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for an intragenic <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and an <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of at least <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 [<a class="bk_pop" href="#sma.REF.parsons.1998.1712">Parsons et al 1998</a>, <a class="bk_pop" href="#sma.REF.wirth.2000.228">Wirth 2000</a>]</p></div></dd><dt>6. </dt><dd><div id="sma.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#sma.REF.bussaglia.1995.335">Bussaglia et al [1995]</a>, <a class="bk_pop" href="#sma.REF.lefebvre.1995.155">Lefebvre et al [1995]</a>, <a class="bk_pop" href="#sma.REF.parsons.1996.1727">Parsons et al [1996]</a>, <a class="bk_pop" href="#sma.REF.hahnen.1997.821">Hahnen et al [1997]</a>, <a class="bk_pop" href="#sma.REF.mcandrew.1997.1411">McAndrew et al [1997]</a>, <a class="bk_pop" href="#sma.REF.talbot.1997.497">Talbot et al [1997]</a>, <a class="bk_pop" href="#sma.REF.ogino.2002.477">Ogino &#x00026; Wilson [2002]</a></p></div></dd><dt>7. </dt><dd><div id="sma.TF.1.7"><p class="no_margin">False negatives may occur because about 5%-8% of the population have two copies of <i>SMN1</i> on a single <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> and a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the other chromosome, known as a [2+0] configuration. Individuals of sub-Saharan African heritage have a higher proportion of the [2+0] configuration [<a class="bk_pop" href="#sma.REF.verhaart.2017.124">Verhaart et al 2017</a>] (see <a href="#sma.Carrier_Heterozygote_Detection">Carrier Detection</a>, <b>Interpretation of the results of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a></b>
<b>testing</b>).</p></div></dd><dt>8. </dt><dd><div id="sma.TF.1.8"><p class="no_margin">Note: Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>SMN2</i> can be performed to provide additional <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> information if the diagnosis of SMA is confirmed on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. The number of copies of <i>SMN2</i> may range from zero to five. Quantitative <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> and MLPA methods are often designed to detect both <i>SMN1</i> and <i>SMN2</i> copy number [<a class="bk_pop" href="#sma.REF.anhuf.2003.74">Anhuf et al 2003</a>, <a class="bk_pop" href="#sma.REF.arkblad.2006.830">Arkblad et al 2006</a>, <a class="bk_pop" href="#sma.REF.scarciolla.2006.269">Scarciolla et al 2006</a>] (see <a href="#sma.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>).</p></div></dd></dl></div></div></div><p><b>Testing to determine <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status</b> is reviewed in <a href="#sma.Carrier_Heterozygote_Detection">Genetic Counseling</a>.</p></div></div></div><div id="sma.Clinical_Characteristics"><h2 id="_sma_Clinical_Characteristics_">Clinical Characteristics</h2><div id="sma.Clinical_Description"><h3>Clinical Description</h3><p>SMA is characterized by muscle weakness and atrophy resulting from progressive degeneration and irreversible loss of the anterior horn cells in the spinal cord (i.e., lower motor neurons) and the brain stem nuclei. The onset of weakness ranges from before birth to adulthood. The weakness is symmetric, proximal greater than distal, and progressive.</p><p>Before the advent of molecular diagnosis, attempts were made to classify SMA into discrete subtypes; however, it is now apparent that the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of SMA associated with <i>SMN1</i> pathogenic variants spans a broad continuum without clear delineation of subtypes. Newly approved treatment options (see <b>Management</b>, <b>Treatment of Manifestations</b>, <a class="figpopup" href="/books/NBK1352/table/sma.T.targeted_treatment_of_spinal_muscu/?report=objectonly" target="object" rid-figpopup="figsmaTtargetedtreatmentofspinalmuscu" rid-ob="figobsmaTtargetedtreatmentofspinalmuscu">Table 7</a>) are changing the natural history of SMA phenotypes and blurring the boundaries even further [<a class="bk_pop" href="#sma.REF.tizzano.2017.883">Tizzano &#x00026; Finkel 2017</a>]. Nonetheless, the existing classification system (<a class="figpopup" href="/books/NBK1352/table/sma.T.spectrum_of_sma_phenotypes_at_pres/?report=objectonly" target="object" rid-figpopup="figsmaTspectrumofsmaphenotypesatpres" rid-ob="figobsmaTspectrumofsmaphenotypesatpres">Table 2</a>) based on age of onset and maximum function attained with supportive care only is useful for prognosis and management.</p><div id="sma.T.spectrum_of_sma_phenotypes_at_pres" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Spectrum of SMA Phenotypes at Presentation</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1352/table/sma.T.spectrum_of_sma_phenotypes_at_pres/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sma.T.spectrum_of_sma_phenotypes_at_pres_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age of Onset</th><th id="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Life Span&#x000a0;<sup>1</sup></th><th id="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Motor Milestones&#x000a0;<sup>1</sup></th><th id="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other Findings&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>SMA 0</b></td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Prenatal</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">A few weeks, &#x0003c;6 mos</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None achieved</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Severe neonatal hypotonia</div></li><li class="half_rhythm"><div>Severe weakness</div></li><li class="half_rhythm"><div>Areflexia</div></li><li class="half_rhythm"><div>Respiratory failure at birth</div></li><li class="half_rhythm"><div>Facial diplegia</div></li><li class="half_rhythm"><div>&#x02193; fetal movements</div></li><li class="half_rhythm"><div>Atrial septal defects</div></li><li class="half_rhythm"><div>Arthrogryposis</div></li></ul>
</td></tr><tr><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>SMA I</b></td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;6 mos</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Median survival 8-10 mos</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Some head control, sit w/support only</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Loss of head control</div></li><li class="half_rhythm"><div>Mild joint contractures</div></li><li class="half_rhythm"><div>Normal or minimal facial weakness</div></li><li class="half_rhythm"><div>Variable suck &#x00026; swallow difficulties</div></li></ul>
</td></tr><tr><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>SMA II</b></td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6-18 mos</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70% alive at age 25 yrs</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Independent sitting when placed</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Developmental delay w/loss of motor skills</div></li><li class="half_rhythm"><div>&#x02193; or absent deep tendon reflexes</div></li><li class="half_rhythm"><div>Proximal muscle weakness</div></li><li class="half_rhythm"><div>Postural tremor of fingers</div></li></ul>
</td></tr><tr><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>SMA III</b></td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;18 mos</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Independent ambulation</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Proximal muscle weakness (i.e., difficulty w/stairs, running)</div></li><li class="half_rhythm"><div>Loss of motor skills</div></li><li class="half_rhythm"><div>Fatigue</div></li><li class="half_rhythm"><div>Postural tremor of fingers</div></li><li class="half_rhythm"><div>Loss of patellar reflexes</div></li></ul>
</td></tr><tr><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>SMA IV</b></td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Adulthood</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_sma.T.spectrum_of_sma_phenotypes_at_pres_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Fatigue</div></li><li class="half_rhythm"><div>Proximal muscle weakness</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="sma.TF.2.1"><p class="no_margin">With supportive care only</p></div></dd></dl></div></div></div><p><b>SMA 0</b> presents with severe weakness, hypotonia, and respiratory distress at birth. There may be a history of decreased in utero movements, joint contractures, and atrial septal defects. Infants with SMA type 0 have severe respiratory compromise/failure and, with supportive care only, rarely survive past age six months [<a class="bk_pop" href="#sma.REF.dubowitz.1999.49">Dubowitz 1999</a>, <a class="bk_pop" href="#sma.REF.macleod.1999.65">MacLeod et al 1999</a>]. There have not been any published reports of infants with SMA 0 who have been treated with nusinersen or <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> (see <a class="figpopup" href="/books/NBK1352/table/sma.T.targeted_treatment_of_spinal_muscu/?report=objectonly" target="object" rid-figpopup="figsmaTtargetedtreatmentofspinalmuscu" rid-ob="figobsmaTtargetedtreatmentofspinalmuscu">Table 7</a>).</p><p><b>SMA I</b> manifests as marked weakness and developmental motor regression before age six months. The mean age of symptom onset is 2.5 months [<a class="bk_pop" href="#sma.REF.lin.2015.293">Lin et al 2015</a>]. Infants may acquire head control and ability to roll, but quickly lose these abilities. With supportive care only, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children do not achieve the ability to sit independently. Proximal, symmetric muscle weakness, lack of motor development with regression of motor function, reduced or absent deep tendon reflexes, and poor muscle tone are the major clinical manifestations. Mild contractures are often noted at the knees and, rarely, at the elbows.</p><p>With supportive care only, fasciculation of the tongue is seen in most but not all infants. While the muscles of the face are relatively spared at initial presentation, bulbar weakness is present in the neonatal period or during the first few months, and infants frequently have problems sucking or swallowing, leading to growth failure and recurrent aspiration. Weakness of the intercostal respiratory muscles with relative preservation of diaphragm musculature leads to characteristic "bell-shaped" chest and paradoxic respiration (abdominal breathing). The diaphragm is not involved until late in the course of disease. Cognitive function is normal. Severe symptomatic bradycardia has been noted in a study of the long-term survival of ventilator-dependent individuals with SMA I [Bach 2017].</p><p>With supportive care only, prospective studies of children with SMA I have shown median survival of 24 months [<a class="bk_pop" href="#sma.REF.oskoui.2007.1931">Oskoui et al 2007</a>]; however, more recent studies have shown a median time to either death or &#x0003e;16 hours/day of ventilation of 8-13.5 months [<a class="bk_pop" href="#sma.REF.finkel.2014.810">Finkel et al 2014</a>, <a class="bk_pop" href="#sma.REF.kolb.2017.883">Kolb et al 2017</a>]. With proactive respiratory and nutritional supportive care, survival is improving [<a class="bk_pop" href="#sma.REF.grychtol.2018.18">Grychtol et al 2018</a>]. Promising new treatments are changing the natural history of SMA I, particularly when treatment is initiated before onset of symptoms (see <a class="figpopup" href="/books/NBK1352/table/sma.T.targeted_treatment_of_spinal_muscu/?report=objectonly" target="object" rid-figpopup="figsmaTtargetedtreatmentofspinalmuscu" rid-ob="figobsmaTtargetedtreatmentofspinalmuscu">Table 7</a>).</p><p><b>SMA II</b> usually manifests between ages six and 12 months; the mean age of symptom onset is 8.3 months [<a class="bk_pop" href="#sma.REF.lin.2015.293">Lin et al 2015</a>]. Although poor muscle tone may be evident at birth or within the first few months of life, individuals with SMA II may gain motor milestones slowly until about age five years. With supportive care only, the maximum motor milestone attained is the ability to sit independently when placed. Affected individuals then have a slow decline in motor function and on average lose the ability to sit independently by the mid-teens [<a class="bk_pop" href="#sma.REF.mercuri.2016.126">Mercuri et al 2016</a>]. Hand tremor is common. Deep tendon reflexes are decreased to absent. Scoliosis is common with progression of disease. Cognition is normal. Cardiac abnormalities are unlikely to develop [<a class="bk_pop" href="#sma.REF.finkel.2018.197">Finkel et al 2018</a>]. Progressive respiratory muscle weakness leads to restrictive lung disease that is associated with morbidity and mortality in these individuals.</p><p>With supportive care only, the life expectancy of persons with SMA II is not known with certainty. A review of life expectancy of 240 individuals with SMA II from Germany and Poland found that 68% of individuals with SMA II were alive at age 25 years [<a class="bk_pop" href="#sma.REF.zerres.1997.67">Zerres et al 1997</a>]. The ability to stand is directly correlated with better pulmonary function and long-term survival. This natural history, however, will likely be improved by newer treatments (see <a class="figpopup" href="/books/NBK1352/table/sma.T.targeted_treatment_of_spinal_muscu/?report=objectonly" target="object" rid-figpopup="figsmaTtargetedtreatmentofspinalmuscu" rid-ob="figobsmaTtargetedtreatmentofspinalmuscu">Table 7</a>).</p><p><b>SMA III</b> typically manifests after age 18 months with a mean age of onset of 39 months &#x000b1; 32.6 months [<a class="bk_pop" href="#sma.REF.lin.2015.293">Lin et al 2015</a>]. The legs are more severely affected than the arms. With supportive care only, individuals walk independently but proximal muscle weakness may lead to more frequent falls or trouble walking up and down stairs. Fatigue can adversely affect quality of life and function significantly.</p><p>Most children with SMA III treated only with supportive care make gains in their motor function until about age six years and then experience a slow decline in function until about puberty. Puberty (until age ~20) may be associated with a more rapid decline in function for adolescents with SMA III.</p><p>With supportive care only, adulthood is then associated with another, much slower decline in function [<a class="bk_pop" href="#sma.REF.montes.2018.e0199657">Montes et al 2018</a>]. Although individuals with SMA III develop the ability to walk, the vast majority will lose that ability with time. If symptom onset is before age three years, loss of ambulation typically occurs in the second decade. However, if symptom onset is between ages three and 12 years, loss of ambulation may occur in the fourth decade [<a class="bk_pop" href="#sma.REF.wadman.2017.365">Wadman et al 2017</a>]. Individuals with SMA III have little to no respiratory muscle weakness. Cardiac and cognitive functions are normal. In a retrospective study of individuals with SMA, the life expectancy of 329 individuals with SMA III from Germany and Poland treated only with supportive care was not different from that of the general population [<a class="bk_pop" href="#sma.REF.zerres.1997.67">Zerres et al 1997</a>]. This natural history, however, will likely be improved by newer treatments (see <a class="figpopup" href="/books/NBK1352/table/sma.T.targeted_treatment_of_spinal_muscu/?report=objectonly" target="object" rid-figpopup="figsmaTtargetedtreatmentofspinalmuscu" rid-ob="figobsmaTtargetedtreatmentofspinalmuscu">Table 7</a>).</p><p><b>SMA IV</b> typically presents with muscle weakness in the second or third decade of life. There is a specific pattern of muscle involvement, with weakness disproportionately affecting the deltoids, triceps, and quadriceps. There may be a loss of patellar reflexes, with sparing of the deep tendon reflexes in the upper extremities and Achilles. Individuals may have a hand tremor. Cardiac and cognitive functioning is normal. With supportive care only, findings are similar to but less severe than those described for SMA III, and if loss of ambulation occurs, it may be after the fifth decade [<a class="bk_pop" href="#sma.REF.brahe.1995.741">Brahe et al 1995</a>, <a class="bk_pop" href="#sma.REF.clermont.1995.1712">Clermont et al 1995</a>, <a class="bk_pop" href="#sma.REF.zerres.1997.67">Zerres et al 1997</a>, <a class="bk_pop" href="#sma.REF.wadman.2017.365">Wadman et al 2017</a>]. Life expectancy is normal. SMA IV is the least common form of SMA and affects fewer than 5% of individuals with SMA [<a class="bk_pop" href="#sma.REF.kolb.2017.883">Kolb et al 2017</a>].</p><div id="sma.Potential_Complications_of_SMA"><h4>Potential Complications of SMA</h4><p>Poor weight gain with growth failure, restrictive lung disease, scoliosis, joint contractures, and sleep difficulties are common complications of SMA in those who receive supportive care only. At this time, it is unknown what long-term complications may arise in individuals who receive early and/or presymptomatic targeted treatment.</p><p><b>Nutrition/gastrointestinal</b></p><ul><li class="half_rhythm"><div>Bulbar dysfunction is universal in individuals with SMA I; the bulbar dysfunction eventually becomes a serious problem for persons with SMA II and only very late in the course of disease for those with SMA III.</div></li><li class="half_rhythm"><div>Gastrointestinal issues may include constipation, delayed gastric emptying, and potentially life-threatening gastroesophageal reflux with aspiration.</div></li><li class="half_rhythm"><div>Growth failure can be addressed with gastrostomy tube placement as needed (see <a href="#sma.Management">Management</a>).</div></li><li class="half_rhythm"><div>Nonambulatory individuals with SMA II and III are at risk of developing obesity [<a class="bk_pop" href="#sma.REF.mercuri.2018.103">Mercuri et al 2018</a>].</div></li></ul><p><b>Respiratory.</b> Children with SMA I and II (and more rarely, type III) who are treated with supportive care only have progressive decline in pulmonary function due to a combination of weak respiratory muscles, reduced chest wall and lung compliance, and a reduction in alveolar multiplication [<a class="bk_pop" href="#sma.REF.chng.2003.673">Chng et al 2003</a>].</p><ul><li class="half_rhythm"><div>Respiratory failure is the most common cause of death in SMA I and II.</div></li><li class="half_rhythm"><div>Decreased respiratory function leads to impaired cough with inadequate clearance of lower airway secretions, hypoventilation during sleep, and recurrent pneumonia.</div></li><li class="half_rhythm"><div>Noninvasive ventilation, such as BiPAP, and airway clearance techniques are commonly used to improve respiratory insufficiency in those with SMA (see <a href="#sma.Management">Management</a>).</div></li></ul><p><b>Orthopedic.</b> Scoliosis, hip dislocation, and joint contractures are common complications in individuals with SMA. Scoliosis is a major problem in most persons with SMA II and in half of those with SMA III. With supportive care only:</p><ul><li class="half_rhythm"><div>Approximately 50% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children (especially those who are nonambulatory) develop spinal curvatures of more than 50 degrees (which require surgery) before age ten years;</div></li><li class="half_rhythm"><div>Later in the disease course, nonambulatory individuals can develop thoracic kyphosis [<a class="bk_pop" href="#sma.REF.mercuri.2018.103">Mercuri et al 2018</a>];</div></li><li class="half_rhythm"><div>Progressive scoliosis impairs lung function and if severe can cause decreased cardiac output [<a class="bk_pop" href="#sma.REF.chng.2003.673">Chng et al 2003</a>].</div></li></ul><p>Use of the vertical expandable prosthetic titanium rib is a possible treatment for severe scoliosis (see <a href="#sma.Management">Management</a>).</p><p><b>Metabolic acidosis.</b> An unexplained potential complication of SMA is severe metabolic acidosis with dicarboxylic aciduria and low serum carnitine concentrations during periods of intercurrent illness or prolonged fasting [<a class="bk_pop" href="#sma.REF.kelley.1986.734">Kelley &#x00026; Sladky 1986</a>].</p><ul><li class="half_rhythm"><div>Whether these metabolic abnormalities are primary or secondary to the underlying defect in SMA is unknown.</div></li><li class="half_rhythm"><div>Although the etiology of these metabolic derangements remains unknown, one report suggests that aberrant glucose metabolism may play a role [<a class="bk_pop" href="#sma.REF.bowerman.2012.256">Bowerman et al 2012</a>].</div></li><li class="half_rhythm"><div>Prolonged fasting should be avoided (see <a href="#sma.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>).</div></li></ul></div><div id="sma.Prognosis"><h4>Prognosis</h4><p>The availability of new targeted treatment options (see <a class="figpopup" href="/books/NBK1352/table/sma.T.targeted_treatment_of_spinal_muscu/?report=objectonly" target="object" rid-figpopup="figsmaTtargetedtreatmentofspinalmuscu" rid-ob="figobsmaTtargetedtreatmentofspinalmuscu">Table 7</a>) will likely change the natural history of this condition. Furthermore, diagnosis prior to symptom onset through <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> programs, coupled with targeted therapies, will likely decrease the morbidity and mortality regardless of treatment strategy.</p></div></div><div id="sma.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><b><i>SMN1</i>.</b> No correlation exists between the type of <i>SMN1</i> pathogenic variants and the severity of disease: the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> is observed with approximately the same frequency in all phenotypes.</p><p><b><i>SMN2</i>.</b> Small amounts (up to a quarter) of full-length transcripts generated by <i>SMN2</i> produce functional protein and result in the milder SMA II or SMA III <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. The number of copies (dosage) of <i>SMN2</i> (arranged in tandem in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration on each <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a>) ranges from zero to five (see <a href="#sma.Molecular_Genetics">Molecular Genetics</a>). The presence of two copies of <i>SMN2</i> is approximately 80% predictive of the SMA I phenotype, whereas the presence of four or more copies of <i>SMN2</i> is approximately 88% predictive of achieving the ability to ambulate with supportive care only (SMA III/IV) [<a class="bk_pop" href="#sma.REF.calucho.2018.208">Calucho et al 2018</a>]. Modifying factors that are not fully understood are likely to contribute to the variability in clinical severity, as can be easily demonstrated with individuals who have three copies of <i>SMN2</i>. Data from <a class="bk_pop" href="#sma.REF.calucho.2018.208">Calucho et al [2018]</a> are summarized in <a class="figpopup" href="/books/NBK1352/table/sma.T.smn2_copy_number_and_sma_clinical/?report=objectonly" target="object" rid-figpopup="figsmaTsmn2copynumberandsmaclinical" rid-ob="figobsmaTsmn2copynumberandsmaclinical">Table 3</a>.</p><div id="sma.T.smn2_copy_number_and_sma_clinical" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>SMN2</i> Copy Number and SMA Clinical Phenotype</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1352/table/sma.T.smn2_copy_number_and_sma_clinical/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sma.T.smn2_copy_number_and_sma_clinical_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_1" style="text-align:left;vertical-align:middle;"><i>SMN2</i> Copy<br />Number</th><th id="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2" colspan="3" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:top;">SMA Clinical Phenotype&#x000a0;<sup>1</sup></th></tr><tr><th headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2" id="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:top;">SMA I</th><th headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2" id="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SMA II&#x000a0;<sup>2</sup></th><th headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2" id="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SMA III/IV&#x000a0;<sup>3</sup></th></tr></thead><tbody><tr><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2 hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">96%</td><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2 hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4%</td><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2 hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0%</td></tr><tr><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2 hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79%</td><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2 hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16%</td><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2 hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5%</td></tr><tr><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2 hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15%</td><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2 hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54%</td><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2 hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31%</td></tr><tr><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">&#x0003e;=4&#x000a0;<sup>4</sup></td><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2 hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1%</td><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2 hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11%</td><td headers="hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_1_2 hd_h_sma.T.smn2_copy_number_and_sma_clinical_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">88%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Adapted from <a class="bk_pop" href="#sma.REF.calucho.2018.208">Calucho et al [2018]</a></p></div></dd><dt>1. </dt><dd><div id="sma.TF.3.1"><p class="no_margin">Clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> with supportive care only</p></div></dd><dt>2. </dt><dd><div id="sma.TF.3.2"><p class="no_margin">With supportive care only, the maximum motor function achieved is sitting.</p></div></dd><dt>3. </dt><dd><div id="sma.TF.3.3"><p class="no_margin">With supportive care only, ambulation is achieved but may not be maintained.</p></div></dd><dt>4. </dt><dd><div id="sma.TF.3.4"><p class="no_margin"><a class="bk_pop" href="#sma.REF.prior.2004.307">Prior et al [2004]</a> reported three asymptomatic, unrelated individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for an <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> who had five copies of <i>SMN2</i>, demonstrating that expression levels consistent with five copies of <i>SMN2</i> may compensate for the lack of <i>SMN1</i> expression.</p></div></dd></dl></div></div></div><p><b>Other putative modifiers of SMA <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a></b></p><ul><li class="half_rhythm"><div>A single-base substitution &#x02013; c.859G&#x0003e;C (p.Gly287Arg) &#x02013; in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 of <i>SMN2</i> has been identified as a disease modifier resulting in a milder disease [<a class="bk_pop" href="#sma.REF.prior.2009.408">Prior et al 2009</a>]. This substitution creates a new exon <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> enhancer (ESE) element. The new ESE increased the amount of exon 7 inclusion and number of full-length transcripts generated from <i>SMN2</i>.</div></li><li class="half_rhythm"><div>In some rare families with unaffected females who have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>SMN1</i> deletions, the expression of plastin 3 (encoded by <i>PLS3</i> at <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> Xq23) was higher than in their SMA-<a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> counterparts. <i>PLS3</i> was shown to be important for axonogenesis and therefore may act as a protective modifier [<a class="bk_pop" href="#sma.REF.oprea.2008.524">Oprea et al 2008</a>].</div></li></ul></div><div id="sma.Nomenclature"><h3>Nomenclature</h3><p>SMA I was previously known as Werdnig-Hoffmann disease or acute SMA [<a class="bk_pop" href="#sma.REF.hoffmann.1892.427">Hoffmann 1892</a>, <a class="bk_pop" href="#sma.REF.werdnig.1971.276">Werdnig 1971</a>].</p><p>SMA II was called chronic SMA or Dubowitz disease prior to the current classification.</p><p>SMA III has had the eponym "Kugelberg-Welander disease" and has also been referred to as juvenile SMA [<a class="bk_pop" href="#sma.REF.kugelberg.1956.500">Kugelberg &#x00026; Welander 1956</a>].</p><p>SMA IV may also be referred to as adolescent- or adult-onset SMA.</p></div><div id="sma.Prevalence"><h3>Prevalence</h3><p>The exact prevalence of SMA is unknown. Historical studies evaluating the prevalence of SMA were limited by lack of genetic confirmation and may underestimate the prevalence of more severe phenotypes due to the shortened life span. It has been suggested that the overall prevalence of SMA is between one and two per 100,000 people [<a class="bk_pop" href="#sma.REF.verhaart.2017.124">Verhaart et al 2017</a>]. In regions or groups with high <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> rates, the incidence of SMA can be higher.</p><div id="sma.T.carrier_frequency_and_incidence_of" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Carrier Frequency and Incidence of SMA</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1352/table/sma.T.carrier_frequency_and_incidence_of/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sma.T.carrier_frequency_and_incidence_of_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Population</th><th id="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Carrier Frequency</th><th id="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Estimated Incidence</th></tr></thead><tbody><tr><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Arab</td><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:59</td><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not reported</td></tr><tr><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asian</td><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:48</td><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:8009</td></tr><tr><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asian Indian</td><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:71</td><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:9655</td></tr><tr><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Black (sub-Saharan African heritage)</td><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:100</td><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:18,808</td></tr><tr><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">White</td><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:45</td><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:7829</td></tr><tr><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hispanic</td><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:77</td><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:20,134</td></tr><tr><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Jewish</td><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:56</td><td headers="hd_h_sma.T.carrier_frequency_and_incidence_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1:10,000</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Adapted from <a class="bk_pop" href="#sma.REF.verhaart.2017.124">Verhaart et al [2017]</a></p></div></dd></dl></div></div></div></div></div><div id="sma.Genetically_Related_Allelic_Disorder"><h2 id="_sma_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those described in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>SMN1</i>.</p></div><div id="sma.Differential_Diagnosis"><h2 id="_sma_Differential_Diagnosis_">Differential Diagnosis</h2><div id="sma.T.disorders_to_consider_in_the_diffe" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of Spinal Muscular Atrophy (SMA)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1352/table/sma.T.disorders_to_consider_in_the_diffe/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sma.T.disorders_to_consider_in_the_diffe_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_1" style="text-align:left;vertical-align:middle;">Age of Onset</th><th id="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" style="text-align:left;vertical-align:middle;">Gene(s) or Region</th><th id="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="2" scope="col" colspan="1" headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Clinical Features of Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5" id="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/SMA</th><th headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5" id="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from SMA</th></tr></thead><tbody><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_1" rowspan="9" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Congenital to &#x0003c;6 mos</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/sma-xli/">X-linked infantile spinal muscular atrophy</a></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>UBA1</i></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypotonia, weakness, areflexia</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multiple <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> contractures, intrauterine fractures</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">SMARD1&#x000a0;<sup>1</sup> (OMIM <a href="http://omim.org/entry/604320" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">604320</a>)</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>IGHMBP2</i></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Weakness, respiratory failure, hypo- or areflexia</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distal predominant weakness, diaphragmatic paralysis</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/pws/">Prader-Willi syndrome</a></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15q11.2-q13&#x000a0;<sup>2</sup></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 2</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypotonia, feeding difficulties</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Poor respiratory effort is rare.</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/myotonic-d/">Myotonic dystrophy type 1</a></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DMPK</i></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypotonia, muscle weakness</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Marked facial weakness</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Congenital muscular dystrophy</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many genes</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />AD</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypotonia, muscle weakness</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CNS, eye involvement, possible increased tone</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/pbd/">Zellweger spectrum disorder</a></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PEX family of genes</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypotonia</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hepatosplenomegaly, CNS</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/cms/">Congenital myasthenic syndromes</a></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CHAT</i><br /><i>CHRNE</i><br /><i>COLQ</i><br /><i>DOK7</i><br /><i>GFPT1</i><br /><i>RAPSN</i>&#x000a0;<sup>3</sup></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />AD</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypotonia</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ophthalmoplegia, ptosis, episodic respiratory failure</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/gsd2/">Pompe disease</a></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GAA</i></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypotonia</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cardiomegaly</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" colspan="5" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Other: <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> myopathies,&#x000a0;<sup>4</sup> metabolic/mitochondrial myopathies,&#x000a0;<sup>5</sup> peripheral neuropathies&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;6 mos</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Botulism</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proximal muscle weakness, decreased reflexes</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Prominent cranial nerve palsies, acute onset</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_1" rowspan="6" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Later childhood</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Guillain-Barr&#x000e9; syndrome</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Muscle weakness</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Subacute onset, sensory involvement</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/dbmd/">Duchenne muscular dystrophy</a></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DMD</i></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Muscle weakness, motor regression</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Serum creatine kinase concentration 10-20x &#x0003e; normal</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/tay-sachs/">Hexosaminidase A deficiency</a> (juvenile, chronic, &#x00026; adult-onset variants)</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HEXA</i></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lower motor neuron disease</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Slow progression, progressive dystonia, spinocerebellar degeneration, cognitive/psychiatric involvement</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Fazio-Londe syndrome (see <a href="/books/n/gene/riboflavin-tn/">Riboflavin Transporter Deficiency Neuronopathy</a>)</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC52A2</i><br /><i>SLC52A3</i></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive bulbar palsy</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Limited to lower cranial nerves; progresses to death in 1-5 yrs</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Monomelic amyotrophy (Hirayama disease) (OMIM <a href="http://omim.org/entry/602440" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">602440</a>)</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Muscle weakness</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predominantly cervical; tongue may be affected (rare); other cranial nerves spared</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" colspan="5" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Other: peripheral neuropathies,&#x000a0;<sup>6</sup> muscular dystrophies&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Adulthood</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/kennedy/">Spinal and bulbar muscular atrophy</a> (Kennedy disease)</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>AR</i></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proximal muscle weakness, muscle atrophy, fasciculations</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gradually progressive; gynecomastia, testicular atrophy, &#x02193; fertility</td></tr><tr><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/als-overview/">Amyotrophic lateral sclerosis</a></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many genes&#x000a0;<sup>8</sup></td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />AR<br />XL</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">May begin w/pure lower motor neuron signs</td><td headers="hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_1_5 hd_h_sma.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive neurodegeneration; involves both upper &#x00026; lower motor neurons</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; SMARD = spinal muscular atrophy with respiratory distress; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="sma.TF.5.1"><p class="no_margin">SMARD spans a phenotypic spectrum [<a class="bk_pop" href="#sma.REF.guenther.2007.808">Guenther et al 2007</a>].</p></div></dd><dt>2. </dt><dd><div id="sma.TF.5.2"><p class="no_margin">Prader-Willi syndrome (PWS) is caused by an absence of expression of <a class="def" href="/books/n/gene/glossary/def-item/imprinted/">imprinted</a> genes in the paternally derived PWS / Angelman syndrome region (15q11.2-q13) of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 15 by one of several genetic mechanisms (paternal <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, maternal <a class="def" href="/books/n/gene/glossary/def-item/uniparental-disomy/">uniparental disomy</a> 15, and rarely an <a class="def" href="/books/n/gene/glossary/def-item/imprinting/">imprinting</a> defect). The risk to the sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child of having PWS depends on the genetic mechanism that resulted in the absence of expression of the paternally contributed 15q11.2-q13 region.</p></div></dd><dt>3. </dt><dd><div id="sma.TF.5.3"><p class="no_margin">Pathogenic variants in one of multiple genes encoding proteins expressed at the neuromuscular junction are currently known to be associated with subtypes of CMS. The most commonly associated genes include those listed in the table (see <a href="/books/n/gene/cms/">Congenital Myasthenic Syndromes</a>).</p></div></dd><dt>4. </dt><dd><div id="sma.TF.5.4"><p class="no_margin">Congenital myopathies: see <a href="/books/n/gene/ccd/">Central Core Disease</a>, <a href="/books/n/gene/nem/">Nemaline Myopathy</a>, <a href="/books/n/gene/mtm/">X-Linked Centronuclear Myopathy</a></p></div></dd><dt>5. </dt><dd><div id="sma.TF.5.5"><p class="no_margin">Metabolic/mitochondrial myopathies: see Glycogen Storage Diseases (<a href="/books/n/gene/gsd1/">GSD I</a>, <a href="/books/n/gene/gsd2/">GSD II</a>, <a href="/books/n/gene/gsd3/">GSD III</a>, <a href="/books/n/gene/gsd4/">GSD IV</a>, <a href="/books/n/gene/gsd5/">GSD V</a>, <a href="/books/n/gene/gsd6/">GSD VI</a>) and <a href="/books/n/gene/mt-overview/">Mitochondrial Disorders Overview</a></p></div></dd><dt>6. </dt><dd><div id="sma.TF.5.6"><p class="no_margin">Peripheral neuropathies: see <a href="/books/n/gene/cmt/">Charcot-Marie-Tooth Hereditary Neuropathy Overview</a></p></div></dd><dt>7. </dt><dd><div id="sma.TF.5.7"><p class="no_margin">Muscular dystrophies: see <a href="/books/n/gene/dbmd/">Dystrophinopathies</a></p></div></dd><dt>8. </dt><dd><div id="sma.TF.5.8"><p class="no_margin">See <a href="http://omim.org/phenotypicSeries/PS105400" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Amyotrophic Lateral Sclerosis: Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p></div></dd></dl></div></div></div><p><b>Trauma of the cervical spinal cord</b> can be considered as well, especially with breech delivery.</p></div><div id="sma.Management"><h2 id="_sma_Management_">Management</h2><p>Detailed recommendations on management of care in individuals with SMA have been published [<a href="https://www.ncbi.nlm.nih.gov/pubmed/29305137" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Finkel et al 2018</a> (full text), <a href="https://www.sciencedirect.com/science/article/pii/S0960896617312841?via%3Dihub" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Mercuri et al 2018</a> (full text)]. Furthermore, treatment algorithms for infants diagnosed through newborn screen have been published [<a href="https://content.iospress.com/articles/journal-of-neuromuscular-diseases/jnd180304" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Glascock et al 2018</a> (full text)].</p><div id="sma.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with SMA, the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual should be referred to a multidisciplinary clinic.</p><p>Regardless of SMA subtype, clinical care should be based on an individual's current functional status. Issues to consider are listed in <a class="figpopup" href="/books/NBK1352/table/sma.T.evaluations_to_consider_following/?report=objectonly" target="object" rid-figpopup="figsmaTevaluationstoconsiderfollowing" rid-ob="figobsmaTevaluationstoconsiderfollowing">Table 6</a>.</p><div id="sma.T.evaluations_to_consider_following" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Evaluations to Consider Following Initial Diagnosis in Individuals with Spinal Muscular Atrophy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1352/table/sma.T.evaluations_to_consider_following/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sma.T.evaluations_to_consider_following_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sma.T.evaluations_to_consider_following_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_sma.T.evaluations_to_consider_following_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_sma.T.evaluations_to_consider_following_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Constitutional</b></td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assessment of growth parameters</td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plotted on a standard growth chart</td></tr><tr><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Gastrointestinal/</b><br /><b>Feeding</b></td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assessment for feeding dysfunction &#x00026; gastroesophageal reflux disease</td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Incl evaluation of aspiration risk,&#x000a0;<sup>1</sup> nutritional status, &#x00026; time required to complete a feed</div></li><li class="half_rhythm"><div>Consider evaluation for gastric tube placement in those w/dysphagia &#x00026;/or aspiration risk.</div></li></ul>
</td></tr><tr><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Assessment for constipation</td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Respiratory</b></td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assessment of pulse oximetry &#x00026; capnography</td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider referral to pulmonologist familiar w/SMA.&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Consider forced vital capacity (FVC), as appropriate to age.</td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>In children age &#x0003e;4-6 yrs, a handheld spirometer is accurate.</div></li><li class="half_rhythm"><div>When FVC is &#x0003e;40%, decompensation during respiratory infection is less likely than when FVC is &#x002c2;40%.</div></li></ul>
</td></tr><tr><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Assessment of airway clearance function by pediatric pulmonologist</td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Consider sleep study (polysomnogram)</td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In all individuals w/type I SMA, in those w/type II who are weak, &#x00026; if clinical evidence of or concern for nocturnal hypoventilation</td></tr><tr><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Orthopedic, physical medicine &#x00026; rehabilitation, PT, &#x00026; OT evaluation</td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Incl assessment of:
<ul><li class="half_rhythm"><div>Gross motor &#x00026; fine motor skills</div></li><li class="half_rhythm"><div>Contractures, hip dislocation, &#x00026; scoliosis</div></li><li class="half_rhythm"><div>Mobility, activities of daily living, &#x00026; need for adaptive devices&#x000a0;<sup>3</sup></div></li><li class="half_rhythm"><div>Need for PT (to improve gross motor skills) &#x00026;/or OT (to improve fine motor skills)</div></li></ul>
</td></tr><tr><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Miscellaneous/</b><br /><b>Other</b></td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Incl <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a></td></tr><tr><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Family support/resources</td><td headers="hd_h_sma.T.evaluations_to_consider_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess:
<ul><li class="half_rhythm"><div>Use of community or online resources such as Parent to Parent</div></li><li class="half_rhythm"><div>Need for social work involvement for parental support</div></li><li class="half_rhythm"><div>Need for home nursing referral</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">OT = occupational therapy; PT = physical therapy</p></div></dd><dt>1. </dt><dd><div id="sma.TF.6.1"><p class="no_margin">Including consideration of a formal videofluoroscopic swallowing study</p></div></dd><dt>2. </dt><dd><div id="sma.TF.6.2"><p class="no_margin"><a class="bk_pop" href="#sma.REF.wang.2007.1027">Wang et al [2007]</a></p></div></dd><dt>3. </dt><dd><div id="sma.TF.6.3"><p class="no_margin">Assess equipment needed for safety (car seat / car bed) and independence, such as power chair and other equipment in the home to improve the quality of life for the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual and the caregiver.</p></div></dd></dl></div></div></div></div><div id="sma.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Currently, there is no cure for SMA. Two treatment options that are targeted to the underlying mechanism that leads to SMA have become available and have been shown to have a positive effect on disease progression (see <a class="figpopup" href="/books/NBK1352/table/sma.T.targeted_treatment_of_spinal_muscu/?report=objectonly" target="object" rid-figpopup="figsmaTtargetedtreatmentofspinalmuscu" rid-ob="figobsmaTtargetedtreatmentofspinalmuscu">Table 7</a>). These treatments are likely to also have a positive impact on the natural history of SMA [<a class="bk_pop" href="#sma.REF.finkel.2017.1723">Finkel et al 2017</a>, <a class="bk_pop" href="#sma.REF.mendell.2017.1713">Mendell et al 2017</a>, <a class="bk_pop" href="#sma.REF.finkel.2018.197">Finkel et al 2018</a>, <a class="bk_pop" href="#sma.REF.mercuri.2018.103">Mercuri et al 2018</a>], particularly if treatment is initiated prior to symptom onset.</p><p>The decision of when to initiate targeted therapy after detection of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual via <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> relies on <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> and presence of symptoms [<a class="bk_pop" href="#sma.REF.glascock.2018.145">Glascock et al 2018</a>]. After confirmatory <i>SMN1</i> genetic testing:</p><ul><li class="half_rhythm"><div>Targeted treatment is recommended for all individuals who have two or three copies of <i>SMN2</i>, regardless of whether symptoms are present;</div></li><li class="half_rhythm"><div>For individuals who have one copy of <i>SMN2</i>, targeted treatment is left to the discretion of the treating physician, taking into account the severity of symptoms, which may have been present prenatally or at birth;</div></li><li class="half_rhythm"><div>For individuals with four or more copies of <i>SMN2</i>, targeted treatment can be deferred until symptom onset, although careful monitoring for the development of symptoms by a neuromuscular expert is recommended.</div></li></ul><div id="sma.T.targeted_treatment_of_spinal_muscu" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Targeted Treatment of Spinal Muscular Atrophy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1352/table/sma.T.targeted_treatment_of_spinal_muscu/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sma.T.targeted_treatment_of_spinal_muscu_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sma.T.targeted_treatment_of_spinal_muscu_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SMA Subtype</th><th id="hd_h_sma.T.targeted_treatment_of_spinal_muscu_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_sma.T.targeted_treatment_of_spinal_muscu_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dosage</th><th id="hd_h_sma.T.targeted_treatment_of_spinal_muscu_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mechanism</th></tr></thead><tbody><tr><td headers="hd_h_sma.T.targeted_treatment_of_spinal_muscu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All<br />subtypes<br />of SMA</td><td headers="hd_h_sma.T.targeted_treatment_of_spinal_muscu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nusinersen (Spinraza<sup>&#x000ae;</sup>)&#x000a0;<sup>1-4</sup></td><td headers="hd_h_sma.T.targeted_treatment_of_spinal_muscu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment regimen:&#x000a0;<sup>5</sup>
<dl class="temp-labeled-list"><dt>1.</dt><dd><p class="no_top_margin">Intrathecal loading dose of 12 mg (equivalent dose; 4-5 mL depending on age) every 14 days for a total of 3 loading doses</p></dd><dt>2.</dt><dd><p class="no_top_margin">4th loading dose 30 days after 3rd dose</p></dd><dt>3.</dt><dd><p class="no_top_margin">Then, maintenance doses every 4 mos</p></dd></dl>
</td><td headers="hd_h_sma.T.targeted_treatment_of_spinal_muscu_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Antisense oligonucleotide&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_sma.T.targeted_treatment_of_spinal_muscu_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SMA type I</td><td headers="hd_h_sma.T.targeted_treatment_of_spinal_muscu_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Onasemnogene abeparvovec-xioi (Zolgensma<sup>&#x000ae;</sup>; formerly AVXS-101)&#x000a0;<sup>7,&#x000a0;8</sup></td><td headers="hd_h_sma.T.targeted_treatment_of_spinal_muscu_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">One-time intravenous injection</td><td headers="hd_h_sma.T.targeted_treatment_of_spinal_muscu_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene replacement therapy w/viral delivery of <i>SMN1</i></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Treatments discussed in this table are targeted to address the underlying mechanism of disease causation and not specifically the signs and symptoms experienced by an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual (see <a class="figpopup" href="/books/NBK1352/table/sma.T.supportive_treatment_of_manifestat/?report=objectonly" target="object" rid-figpopup="figsmaTsupportivetreatmentofmanifestat" rid-ob="figobsmaTsupportivetreatmentofmanifestat">Table 8</a>).</p></div></dd><dt>1. </dt><dd><div id="sma.TF.7.1"><p class="no_margin">In the double-blind, sham-controlled Phase III clinical trial of nusinersen in 121 infants with SMA type I, 51% of treated infants showed acquisition of a new motor milestone as assessed by the Hammersmith Infant Neurological Examination (HINE) compared with 0% of controls [<a class="bk_pop" href="#sma.REF.finkel.2017.1723">Finkel et al 2017</a>].</p></div></dd><dt>2. </dt><dd><div id="sma.TF.7.2"><p class="no_margin">Further, event-free survival ("event" defined as death or requirement for permanent assisted ventilation) was higher in the nusinersen group than in the control group (hazard ratio 0.53; P=0.005) as was the likelihood of overall survival (hazard ratio 0.37; P=0.004) [<a class="bk_pop" href="#sma.REF.finkel.2017.1723">Finkel et al 2017</a>].</p></div></dd><dt>3. </dt><dd><div id="sma.TF.7.3"><p class="no_margin">In the parallel double-blind, sham-controlled, Phase III trial including 126 children with later-onset SMA, those who received nusinersen had significant and clinically meaningful improvement in motor function as compared with those in the control group [<a class="bk_pop" href="#sma.REF.mercuri.2018.103">Mercuri et al 2018</a>].</p></div></dd><dt>4. </dt><dd><div id="sma.TF.7.4"><p class="no_margin">The efficacy of treatment with nusinersen in those who already have symptoms is not completely understood [<a class="bk_pop" href="#sma.REF.shorrock.2018.293">Shorrock et al 2018</a>, <a class="bk_pop" href="#sma.REF.gidaro.2019.19">Gidaro &#x00026; Servais 2019</a>].</p></div></dd><dt>5. </dt><dd><div id="sma.TF.7.5"><p class="no_margin"><a class="bk_pop" href="#sma.REF.shorrock.2018.293">Shorrock et al [2018]</a></p></div></dd><dt>6. </dt><dd><div id="sma.TF.7.6"><p class="no_margin">The antisense oligonucleotide is a single-stranded RNA molecule that is specifically designed to bind to the ISS-N1 regulatory motif in the <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> downstream of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 in the <i>SMN2</i> pre-mMRA [<a class="bk_pop" href="#sma.REF.rigo.2014.46">Rigo et al 2014</a>]. Binding at this site promotes inclusion of exon 7, leading to increased full-length <i>SMN</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> and thus full-length SMN protein.</p></div></dd><dt>7. </dt><dd><div id="sma.TF.7.7"><p class="no_margin">A Phase I trial in 15 individuals with SMA type I showed event-free survival ("event" = death or need for permanent ventilator assistance) at age 20 months in all 15 compared with only 8% of historical controls [<a class="bk_pop" href="#sma.REF.mendell.2017.1713">Mendell et al 2017</a>].</p></div></dd><dt>8. </dt><dd><div id="sma.TF.7.8"><p class="no_margin">Treated individuals showed an improvement in motor milestones and an increase from baseline in objective motor function scales.</p></div></dd></dl></div></div></div><p>Supportive treatment of children with SMA is guided by the underlying subtype but should be individualized to the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual and his/her current functional status (nonsitter, sitter, or walker) [<a class="bk_pop" href="#sma.REF.finkel.2018.197">Finkel et al 2018</a>]. The proportion of affected individuals who develop a given complication and the severity of the complication depends on which subtype of SMA is involved and whether targeted treatment is initiated before or after symptom onset [<a class="bk_pop" href="#sma.REF.shorrock.2018.293">Shorrock et al 2018</a>] (see <a class="figpopup" href="/books/NBK1352/table/sma.T.supportive_treatment_of_manifestat/?report=objectonly" target="object" rid-figpopup="figsmaTsupportivetreatmentofmanifestat" rid-ob="figobsmaTsupportivetreatmentofmanifestat">Table 8</a>).</p><div id="sma.T.supportive_treatment_of_manifestat" class="table"><h3><span class="label">Table 8. </span></h3><div class="caption"><p>Supportive Treatment of Manifestations in Individuals with Spinal Muscular Atrophy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1352/table/sma.T.supportive_treatment_of_manifestat/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sma.T.supportive_treatment_of_manifestat_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/<br />Concern</th><th id="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Bulbar dysfunction</b><br /><b>leading to poor</b><br /><b>weight gain</b></td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Placement of gastrostomy tube &#x00026; nutritional supplementation</td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Most individuals w/SMA I have a gastrostomy tube by age 12 mos.&#x000a0;<sup>1</sup></div></li><li class="half_rhythm"><div>Low threshold for clinical feeding evaluation &#x00026;/or radiographic swallowing study if clinical signs or symptoms of dysphagia &#x00026;/or bulbar dysfunction</div></li></ul>
</td></tr><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Obesity</b></td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Regular nutritional evaluations</td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For nonambulatory individuals w/SMA II &#x00026; III</td></tr><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Gastroesophageal</b><br /><b>reflux disease</b></td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment</td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Bowel</b><br /><b>dysfunction</b></td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stool softeners, prokinetics, osmotic agents, or laxatives as needed</td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For constipation</td></tr><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Respiratory insufficiency/</b><br /><b>failure options&#x000a0;<sup>3,&#x000a0;4</sup></b></td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Palliative care &#x00026;/or no respiratory support</td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">May be an option depending on family preference&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Airway clearance techniques &#x00026; secretion management&#x000a0;<sup>5</sup></td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Incl mechanical in-exsufflator in conjunction w/suctioning &#x00026; chest physiotherapy, particularly during acute illness</div></li><li class="half_rhythm"><div>Use of mechanical in-exsufflation in treatment of children w/neuromuscular diseases (incl those w/SMA) appears to reduce pulmonary complications.</div></li></ul>
</td></tr><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Noninvasive ventilation,&#x000a0;<sup>5</sup> such as BiPAP</td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>For hypoventilation as demonstrated by &#x02193; oxygen saturation by pulse oximetry or by obstructive sleep apnea&#x000a0;<sup>6</sup></div></li><li class="half_rhythm"><div>Has been shown to improve sleep breathing parameters in those w/SMA I &#x00026; II&#x000a0;<sup>7</sup></div></li><li class="half_rhythm"><div>BiPAP may improve chest wall &#x00026; lung development, which may reduce lung infections &#x00026; pulmonary comorbidity.</div></li></ul>
</td></tr><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Tracheotomy w/permanent mechanical ventilation</td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ethical questions re use of invasive ventilation in severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infants must be addressed.&#x000a0;<sup>8</sup></td></tr><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Progressive</b><br /><b>scoliosis</b></td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard surgical intervention per orthopedist</td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Use of spinal orthosis for curvatures &#x0003e;20&#x000b0; prior to surgical intervention is common.&#x000a0;<sup>9</sup></div></li><li class="half_rhythm"><div>Important consideration in spinal surgery: leave a window for possibility of intrathecal administration of future treatments.&#x000a0;<sup>10</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Consider vertical expandable prosthetic titanium rib (VEPTR).&#x000a0;<sup>11</sup></td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For severe scoliosis</td></tr><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Consider magnetically controlled growing rods (MGR).</td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>For gradual outpatient distractions controlled by an external remote device&#x000a0;<sup>12</sup></div></li><li class="half_rhythm"><div>May &#x02193; need for repeated surgery&#x000a0;<sup>13</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hip dislocation</b></td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider surgery for those who have pain.</td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No surgery for those who are asymptomatic&#x000a0;<sup>14</sup></td></tr><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Metabolic acidosis</b><br /><b>during intercurrent</b><br /><b>illness</b></td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Supportive care w/early intravenous fluids &#x00026; glucose</td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Family/</b><br /><b>Community</b></td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ensure appropriate social work involvement to connect families w/local resources, respite, &#x00026; support.</td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ongoing assessment of need for palliative care involvement &#x00026;/or home nursing</td></tr><tr><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Coordinate care to manage multiple subspecialty appointments, equipment, medications, &#x00026; supplies.</td><td headers="hd_h_sma.T.supportive_treatment_of_manifestat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="sma.TF.8.1"><p class="no_margin">In those who receive supportive care only [<a class="bk_pop" href="#sma.REF.finkel.2014.810">Finkel et al 2014</a>]</p></div></dd><dt>2. </dt><dd><div id="sma.TF.8.2"><p class="no_margin">See <a class="figpopup" href="/books/NBK1352/table/sma.T.targeted_treatment_of_spinal_muscu/?report=objectonly" target="object" rid-figpopup="figsmaTtargetedtreatmentofspinalmuscu" rid-ob="figobsmaTtargetedtreatmentofspinalmuscu">Table 7</a> for targeted treatment options that may improve lung function in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div></dd><dt>3. </dt><dd><div id="sma.TF.8.3"><p class="no_margin">Options should be discussed with parents / care providers before respiratory failure occurs.</p></div></dd><dt>4. </dt><dd><div id="sma.TF.8.4"><p class="no_margin">The type of respiratory support is dependent on the individual's respiratory status, quality-of-life goals, and access to equipment.</p></div></dd><dt>5. </dt><dd><div id="sma.TF.8.5"><p class="no_margin">Noninvasive pulmonary intervention should be incorporated into the management of all types of SMA.</p></div></dd><dt>6. </dt><dd><div id="sma.TF.8.6"><p class="no_margin"><a class="bk_pop" href="#sma.REF.chatwin.2003.502">Chatwin et al [2003]</a>, <a class="bk_pop" href="#sma.REF.miske.2004.1406">Miske et al [2004]</a></p></div></dd><dt>7. </dt><dd><div id="sma.TF.8.7"><p class="no_margin"><a class="bk_pop" href="#sma.REF.petrone.2007.216">Petrone et al [2007]</a></p></div></dd><dt>8. </dt><dd><div id="sma.TF.8.8"><p class="no_margin"><a class="bk_pop" href="#sma.REF.finkel.2018.197">Finkel et al [2018]</a>, <a class="bk_pop" href="#sma.REF.grychtol.2018.18">Grychtol et al [2018]</a></p></div></dd><dt>9. </dt><dd><div id="sma.TF.8.9"><p class="no_margin">There is insufficient evidence that spinal orthotics alter scoliosis in SMA.</p></div></dd><dt>10. </dt><dd><div id="sma.TF.8.10"><p class="no_margin"><a class="bk_pop" href="#sma.REF.mercuri.2018.103">Mercuri et al [2018]</a></p></div></dd><dt>11. </dt><dd><div id="sma.TF.8.11"><p class="no_margin"><a class="bk_pop" href="#sma.REF.chandran.2011.450">Chandran and colleagues [2011]</a> described the use of VEPTR in 11 children with SMA types I and II who were followed for an average of 43 months after the initial surgery. The average age at time of surgery was six years. No surgical complications were identified. Medical complications were seen in two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals: postoperative pneumonia and anemia.</p></div></dd><dt>12. </dt><dd><div id="sma.TF.8.12"><p class="no_margin">A small case series of individuals with neuromuscular disorders (2 of whom had SMA) evaluated MGR and pulmonary function. Affected individuals showed an improvement in forced vital capacity and FEV1 (forced expired volume in 1 second) postoperatively with spinal deformity correction, with very few complications [<a class="bk_pop" href="#sma.REF.yoon.2014.1196">Yoon et al 2014</a>].</p></div></dd><dt>13. </dt><dd><div id="sma.TF.8.13"><p class="no_margin"><a class="bk_pop" href="#sma.REF.finkel.2018.197">Finkel et al [2018]</a></p></div></dd><dt>14. </dt><dd><div id="sma.TF.8.14"><p class="no_margin"><a class="bk_pop" href="#sma.REF.sporer.2003.10">Sporer &#x00026; Smith [2003]</a></p></div></dd></dl></div></div></div></div><div id="sma.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>See <a class="figpopup" href="/books/NBK1352/table/sma.T.targeted_treatment_of_spinal_muscu/?report=objectonly" target="object" rid-figpopup="figsmaTtargetedtreatmentofspinalmuscu" rid-ob="figobsmaTtargetedtreatmentofspinalmuscu">Table 7</a>.</p></div><div id="sma.Surveillance"><h3>Surveillance</h3><p>Presymptomatic individuals should be monitored for the development of symptoms to determine appropriate timing to initiate targeted and/or supportive therapies. A treatment algorithm for the evaluation of presymptomatic infants has been published [<a class="bk_pop" href="#sma.REF.glascock.2018.145">Glascock et al 2018</a>].</p><p>Individuals with SMA are evaluated at least every six months; weaker children are evaluated more frequently.</p><p>Multidisciplinary surveillance at each visit includes assessments of nutritional state, respiratory function, and orthopedic status (spine, hips, and joint range of motion).</p></div><div id="sma.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Prolonged fasting should be avoided, particularly in the acutely ill infant with SMA [<a class="bk_pop" href="#sma.REF.mercuri.2018.103">Mercuri et al 2018</a>].</p></div><div id="sma.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to determine the genetic status of younger, apparently asymptomatic sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from prompt initiation of targeted treatment and preventive measures.</p><p>See <a href="#sma.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="sma.Pregnancy_Management"><h3>Pregnancy Management</h3><p>There have been two published studies surveying the pregnancy experience of women with SMA [<a class="bk_pop" href="#sma.REF.awater.2012.153">Awater et al 2012</a>, <a class="bk_pop" href="#sma.REF.elsheikh.2017.953">Elsheikh et al 2017</a>] as well as an international workshop on pregnancy in neuromuscular disorders [<a class="bk_pop" href="#sma.REF.norwood.2012.183">Norwood &#x00026; Rudnik-Sch&#x000f6;neborn 2012</a>]. From the collective experience, it appears that women with SMA may have an increased rate of preterm birth (27%) and need for cesarean section (41%) [<a class="bk_pop" href="#sma.REF.awater.2012.153">Awater et al 2012</a>, <a class="bk_pop" href="#sma.REF.elsheikh.2017.953">Elsheikh et al 2017</a>] compared to unaffected women. While local anesthesia is preferred to general anesthesia in women with SMA, an epidural can be difficult in people with severe scoliosis or spinal fusions [<a class="bk_pop" href="#sma.REF.awater.2012.153">Awater et al 2012</a>, <a class="bk_pop" href="#sma.REF.finkel.2018.197">Finkel et al 2018</a>]. Women with SMA may also experience a persistent worsening of their general muscle weakness after delivery (32%) [<a class="bk_pop" href="#sma.REF.awater.2012.153">Awater et al 2012</a>, <a class="bk_pop" href="#sma.REF.elsheikh.2017.953">Elsheikh et al 2017</a>]. Severe respiratory distress with maternal hypercapnia and hypoxemia was attributed to one stillbirth at 26 weeks' gestation [<a class="bk_pop" href="#sma.REF.awater.2012.153">Awater et al 2012</a>]. Due to the risk of respiratory failure, it is recommended that women with neuromuscular disorders, including those with SMA, obtain baseline pulmonary function prior to becoming pregnant, with frequent monitoring during pregnancy [<a class="bk_pop" href="#sma.REF.norwood.2012.183">Norwood &#x00026; Rudnik-Sch&#x000f6;neborn 2012</a>].</p><p>No human pregnancies have been reported to have occurred during/after treatment with nusinersen. It is also unknown if nusinersen is excreted through human breast milk. Animal models do not show an increased risk for adverse fetal outcome with nusinersen exposure, or risk for future male or female infertility. However, as the risk to a developing human fetus has not been determined, it has been recommended that women discontinue treatment with nusinersen prior to conception.</p><p>There have not been any reported cases of pregnant women with SMA treated with <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a>.</p></div><div id="sma.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>A number of different therapeutic approaches are in development, including further studies on the approved therapeutics discussed above. Newer approaches (including some directed at increasing full-length SMN protein from <i>SMN2</i>, use of <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> to restore <i>SMN1</i>, and SMN-independent approaches) are being actively investigated; see <a class="bk_pop" href="#sma.REF.shorrock.2018.293">Shorrock et al [2018]</a>.</p><p><b><i>SMN2-</i>targeted therapeutic approaches.</b> Therapeutic approaches in this category aim to alter <i>SMN2</i> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> to increase the proportion of transcripts containing <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 and thus increase full-length SMN protein. Antisense oligonucleotides are single-stranded RNA molecules specifically designed to target complementary sequences in the SMN2 transcript leading to inclusion of exon 7. Nusinersen also works through this mechanism. At least two additional <i>SNM2</i> splicing modifiers are currently in clinical trials in SMA, including Novartis Pharmaceuticals LMI070 (<a href="https://clinicaltrials.gov/ct2/results?term=NCT02268552&#x00026;Search=Search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NCT02268552</a>) and Roche RG7916 (<a href="https://clinicaltrials.gov/ct2/results?term=NCT02633709&#x00026;Search=Search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NCT02633709</a>). Both of these agents are delivered orally. Results of these trials are not yet available.</p><p><b>SMN-independent approaches.</b> Molecules directed at increasing muscle strength in individuals with SMA are also under investigation. CK-107 is a tropinin complex activator proposed to cause increased muscle force output [<a class="bk_pop" href="#sma.REF.andrews.2018.729">Andrews et al 2018</a>]. This molecule is being studied in a Phase II trial (<a href="https://clinicaltrials.gov/ct2/results?cond=&#x00026;term=NCT02644668&#x00026;cntry=&#x00026;state=&#x00026;city=&#x00026;dist=" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NCT02644668</a>) in individuals with SMA II-IV. The trial has recently completed enrollment; results are not yet available.</p><p>A myostatin inhibitor SRK-015 has recently initiated enrollment in a Phase II trial (<a href="https://clinicaltrials.gov/ct2/results?cond=&#x00026;term=NCT03921528&#x00026;cntry=&#x00026;state=&#x00026;city=&#x00026;dist=" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NCT03921528</a>) in those with SMA II or III [<a class="bk_pop" href="#sma.REF.long.2019.1076">Long et al 2019</a>].</p><p>Search <a href="http://www.ClinicalTrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="sma.Genetic_Counseling"><h2 id="_sma_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="sma.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Spinal muscular atrophy is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="sma.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Approximately 98% of parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are heterozygotes (i.e., carriers of one <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>About 2% of parents are not carriers of an <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, as their <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child has a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant [<a class="bk_pop" href="#sma.REF.wirth.1997.1102">Wirth et al 1997</a>]. The majority of <i>de novo</i> pathogenic variants are paternal in origin [<a class="bk_pop" href="#sma.REF.wirth.1997.1102">Wirth et al 1997</a>].</div></li><li class="half_rhythm"><div>Heterozygotes are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has an approximately 25% chance of being affected, an approximately 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and an approximately 25% chance of being unaffected and not a carrier.</div><div class="half_rhythm">Note: Recurrence risk in sibs is the same (i.e., ~25%) if one parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a [2+0] <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> (see <a href="#sma.Carrier_Heterozygote_Detection">Carrier Detection</a>) and the other parent has an <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> [1+0] or <i>SMN1</i> intragenic variant.</div></li><li class="half_rhythm"><div class="half_rhythm">Recurrence risk in sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> known to have been inherited from a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> parent and one apparently <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant (i.e., one of the parents does not have an identifiable <i>SMN1</i> pathogenic variant) is presumed to be low. However, due to the possibility that the parent in whom an <i>SMN1</i> pathogenic variant was not identified has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> for an <i>SMN1</i> variant, these sibs should still be considered at risk for SMA [<a class="bk_pop" href="#sma.REF.campbell.1998.37">Campbell et al 1998</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The offspring of an individual with SMA are obligate heterozygotes for an <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>The unrelated reproductive partner of an individual with SMA should be offered <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a>. If the partner shows at least two <i>SMN1</i> copies, the partner has a one-in-670 probability of being a carrier (taking into consideration the 2% frequency of two <i>SMN1</i> copies on the same <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> and the small risk of an intragenic <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>). Thus, the risk to such a couple of having an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child is one in 1,340.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="sma.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Molecular genetic testing to determine <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status is recommended for:</p><ul><li class="half_rhythm"><div>Parents of more than one child with molecularly confirmed SMA;</div></li><li class="half_rhythm"><div>Parents of a child with molecularly confirmed SMA who represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family);</div></li><li class="half_rhythm"><div>Parents of a child with suspected but not molecularly confirmed SMA;</div></li><li class="half_rhythm"><div>Persons not known to have a family history of SMA (see <a href="#sma.Population_Screening">Population Screening</a>) who are reproductive partners of known carriers.</div></li></ul><p>Note: Preconception <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> screening for SMA in individuals with and without a family history of SMA has been recommended by the <a href="https://www.acmg.net/PDFLibrary/Spinal-Muscular-Atrophy-Carrier-Screening.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ACMG</a> and <a href="https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Genetics/Carrier-Screening-for-Genetic-Conditions" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ACOG</a> (see <a href="#sma.Population_Screening">Population Screening</a>).</p><p><b>Interpretation of the results of <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a>.</b> Approximately 6% of parents of a child with SMA resulting from a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> have normal results of <i>SMN1</i> dosage testing for the following two reasons:</p><ul><li class="half_rhythm"><div>About 4% of carriers have two copies of <i>SMN1</i> on a single <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> [<a class="bk_pop" href="#sma.REF.mcandrew.1997.1411">McAndrew et al 1997</a>]. These <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> individuals with two copies of <i>SMN1</i> on one chromosome (a [2+0] <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>) are misdiagnosed as non-carriers by the <i>SMN1</i> dosage test (i.e., a false negative test result). A specific haplotype block is associated with a [2+0] genotype in the <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> population [<a class="bk_pop" href="#sma.REF.luo.2014.149">Luo et al 2014</a>] and in black individuals of sub-Saharan African heritage [<a class="bk_pop" href="#sma.REF.verhaart.2017.124">Verhaart et al 2017</a>].</div></li><li class="half_rhythm"><div><i>De novo</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 of one <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> occurs in 2% of individuals with SMA; thus, only one parent is a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</div></li><li class="half_rhythm"><div>In the United States pan ethnic population, the calculated a priori <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency is 1/54 with a detection rate of 91.2%. Therefore, an individual from this pan ethnic population with normal <i>SMN1</i> dosage testing would have a ~1/500 residual risk of being a carrier [<a class="bk_pop" href="#sma.REF.sugarman.2012.27">Sugarman et al 2012</a>].</div></li></ul><div id="sma.Determining_Carrier_Status"><h4>Determining Carrier Status</h4><p><b>In parents of a child with molecularly confirmed SMA.</b> If the child is confirmed to have <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 deleted from both copies of <i>SMN1</i>, first perform <i>SMN1</i> dosage analysis on both parents:</p><ul><li class="half_rhythm"><div>If <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 is found to be deleted from one copy of <i>SMN1</i> in both parents, <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status is confirmed in the parents.</div></li><li class="half_rhythm"><div>If <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 is found to be deleted from one copy of <i>SMN1</i> in only one parent, the following are possible explanations:</div><ul><li class="half_rhythm"><div class="half_rhythm">The parent in whom the <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> was not identified may have one <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 5 with two copies of <i>SMN1</i> and one chromosome 5 with no copies of <i>SMN1</i> (i.e., a [2+0] <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>).</div><div class="half_rhythm">Note: (1) Testing additional family members of the parent with the [2+0] <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> may be informative: usually one of his/her parents has a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> (1/0 <i>SMN1</i> genotype) and the other parent has three or more <i>SMN1</i> copies (2/1 <i>SMN1</i> genotype). (2) If the parent of a child with SMA who has one <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 5 with two copies of <i>SMN1</i> and one chromosome 5 with no copies of <i>SMN1</i> (i.e., a [2+0] <i>SMN1</i> genotype) has children with a known <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, the children are at 25% risk of having SMA as the result of inheriting the chromosome 5 with no copies of <i>SMN1</i> from this parent and the chromosome 5 with the <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 deletion or <i>SMN1</i> intragenic <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from the carrier parent.</div></li><li class="half_rhythm"><div class="half_rhythm">The child may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 (if the child represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case [i.e., a single occurrence in a family]).</div></li><li class="half_rhythm"><div class="half_rhythm">Non-paternity</div></li></ul></li></ul><p>If the child is confirmed to have <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 deleted from one copy of <i>SMN1</i> and an intragenic <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the other copy of <i>SMN1</i>, first perform <i>SMN1</i> dosage analysis on both parents:</p><ul><li class="half_rhythm"><div>Typically, one parent is found to have the <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>.</div></li><li class="half_rhythm"><div>Molecular genetic testing for the intragenic <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the child should be performed on the parent in whom the <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> was not detected.</div></li><li class="half_rhythm"><div>If the intragenic <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified in the parent, <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status is confirmed in that parent.</div></li><li class="half_rhythm"><div>If the intragenic <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the child is not identified in the parent, possible explanations include:</div><ul><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> intragenic <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the child (if the child represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case [i.e., a single occurrence in a family]);</div></li><li class="half_rhythm"><div>Germline <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> for the intragenic <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the parent;</div></li><li class="half_rhythm"><div>Non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption.</div></li></ul></li></ul><p><b>In parents of a deceased child with suspected but not molecularly confirmed SMA.</b> As a first step, attempt to test any available tissue samples, such as muscle biopsies (even if imbedded in paraffin) and blood spots from <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a>, as these samples can <b>often</b> provide enough DNA for <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p>If DNA is not available, perform <i>SMN1</i> dosage analysis on both parents:</p><ul><li class="half_rhythm"><div>If <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 is found to be deleted from one copy of <i>SMN1</i> in both parents, <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status is confirmed in the parents.</div></li><li class="half_rhythm"><div>If <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 is found to be deleted from one copy of <i>SMN1</i> in only one parent, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>SMN1</i> should be considered in the parent in whom the <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> was not detected.</div></li><li class="half_rhythm"><div>If <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 is not found to be deleted from one copy of <i>SMN1</i> in either parent, alternate diagnoses should be considered.</div></li></ul></div><div id="sma.Population_Screening"><h4>Population Screening</h4><p>Preconception <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> screening for SMA in individuals not known to have a family history of SMA has been recommended by the <a href="https://www.acmg.net/PDFLibrary/Spinal-Muscular-Atrophy-Carrier-Screening.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ACMG</a> and <a href="https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Genetics/Carrier-Screening-for-Genetic-Conditions" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ACOG</a>. Carrier screening for persons not known to have a family history of SMA requires <i>SMN1</i> dosage analysis. If such an individual is found to have at least two <i>SMN1</i> copies, the probability of being a carrier is approximately 1/670 (taking into consideration the 2% frequency of two <i>SMN1</i> copies on the same <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> and the small risk of being a carrier for an intragenic <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</p><p>Note: In the general population most people have one copy of <i>SMN1</i> on each <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> ([1+1] configuration); however, about 5%-8% of the population have two copies of <i>SMN1</i> on a single chromosome and a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the other chromosome, known as a [2+0] configuration. Black individuals of sub-Saharan African heritage have a higher proportion of the [2+0] configuration and have a lower detection rate (70%) than other populations [<a class="bk_pop" href="#sma.REF.verhaart.2017.124">Verhaart et al 2017</a>]. Individuals with a [2+0] <i>SMN1</i> configuration will have a false negative <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> screening result with the most common forms of <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a>.</p></div></div><div id="sma.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#sma.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="sma.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p><b>High-risk pregnancy.</b> Once the <i>SMN1</i> pathogenic variants in both parents are known or linkage has been established in the family, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> for SMA [<a class="bk_pop" href="#sma.REF.moutou.2003.685">Moutou et al 2003</a>, <a class="bk_pop" href="#sma.REF.malcov.2004.199">Malcov et al 2004</a>] are possible. Although it would be predicted that a fetus with the same <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> (i.e., molecular genetic test result) as a previously <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sib would have similar clinical findings, there can be <a class="def" href="/books/n/gene/glossary/def-item/intrafamilial-variability/">intrafamilial variability</a> in phenotypic presentation. An <i>SMN2</i> copy number determination on the prenatal specimen may help to better predict the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of the affected child.</p><p>Note: Interpretation of test results and prediction of clinical findings in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child may be difficult and should be done in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>.</p><p><b>Low-risk pregnancy.</b> For the fetus with reduced fetal movement at no known increased risk for SMA, SMA needs to be considered, as do the disorders discussed in the <a href="#sma.Differential_Diagnosis">Differential Diagnosis</a> [<a class="bk_pop" href="#sma.REF.macleod.1999.65">MacLeod et al 1999</a>].</p></div></div><div id="sma.Resources"><h2 id="_sma_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Cure SMA</b></div><div>925 Busse Road</div><div>Elk Grove Village IL 60007</div><div><b>Phone:</b> 800-886-1762 (toll-free)</div><div><b>Email:</b> familysupport@curesma.org</div><div><a href="http://www.curesma.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.curesma.org</a></div></li><li class="half_rhythm"><div><b>FightSMA Canada</b></div><div>Canada</div><div><a href="http://www.fightsma.ca/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fightsma.ca</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy Association - USA (MDA)</b></div><div>222 South Riverside Plaza</div><div>Suite 1500</div><div>Chicago IL 60606</div><div><b>Phone:</b> 800-572-1717</div><div><b>Email:</b> mda@mdausa.org</div><div><a href="http://www.mda.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mda.org</a></div></li><li class="half_rhythm"><div><b>National Organization for Rare Disorders (NORD)</b></div><div>55 Kenosia Avenue</div><div>PO Box 1968</div><div>Danbury CT 06813-1968</div><div><b>Phone:</b> 800-999-6673 (toll-free); 203-744-0100; 203-797-9590 (TDD)</div><div><b>Fax:</b> 203-798-2291</div><div><b>Email:</b> RN@rarediseases.org; genetic_counselor@rarediseases.org; orphan@rarediseases.org</div><div><a href="http://rarediseases.org/rare-diseases/spinal-muscular-atrophy/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Spinal Muscular Atrophy</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22213/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Spinal muscular atrophy</a></div></li><li class="half_rhythm"><div><b>The Gwendolyn Strong Foundation</b></div><div>27 West Anapamu Street</div><div>Suite 177</div><div>Santa Barbara CA 93101</div><div><a href="http://thegsf.org/home/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.thegsf.org</a></div></li><li class="half_rhythm"><div><b>Claire Altman Heine Foundation, Inc.</b></div><div><i>A foundation whose focus is support and funding of population-based SMA <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> screening, and increasing awareness of SMA in both the public and medical communities</i></div><div>1112 Montana Avenue</div><div>#372</div><div>Santa Monica CA 90403</div><div><b>Phone:</b> 310-260-3262</div><div><b>Fax:</b> 310-393-7154</div><div><b>Email:</b> deb@preventsma.org</div><div><a href="http://www.clairealtmanheinefoundation.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.clairealtmanheinefoundation.org</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/spinalmuscularatrophy.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Spinal Muscular Atrophy</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Spinal%20muscular%20atrophy&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Spinal muscular atrophy</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=spinalmuscularatrophy" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Spinal muscular atrophy</a></div></li><li class="half_rhythm"><div><b>International SMA Patient Registry</b></div><div>Indiana University School of Medicine, Department of Medical &#x00026; Molecular Genetics </div><div>410 West Tenth Street</div><div>HS 4000</div><div>Indianapolis IN 46202-3002</div><div><b>Phone:</b> 866-482-0248</div><div><b>Fax:</b> 317-278-1100 </div><div><b>Email:</b> smareg@iupui.edu</div><div><a href="http://smaregistry.iu.edu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">smaregistry.iu.edu</a></div></li></ul></div><div id="sma.Molecular_Genetics"><h2 id="_sma_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="sma.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Spinal Muscular Atrophy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1352/table/sma.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sma.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_sma.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_sma.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_sma.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_sma.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_sma.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_sma.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_sma.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/6606" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SMN1</i></a></td><td headers="hd_b_sma.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=6606" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">5q13<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_sma.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q16637" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Survival motor neuron protein</a></td><td headers="hd_b_sma.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://alsod.iop.kcl.ac.uk/Als/Overview/gene.aspx?gene_id=SMN1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">alsod/SMN1 genetic mutations</a><br /><a href="http://reseq.biosciencedbc.jp/resequence/GeneDetail.do?targetId=1&#x00026;geneId=EG6606" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALS mutation database (SMN1)</a><br /><a href="https://databases.lovd.nl/shared/genes/SMN1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMN1 homepage - Leiden Muscular Dystrophy pages</a></td><td headers="hd_b_sma.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SMN1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMN1</a></td><td headers="hd_b_sma.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SMN1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMN1</a></td></tr><tr><td headers="hd_b_sma.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/6607" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SMN2</i></a></td><td headers="hd_b_sma.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=6607" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">5q13<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_sma.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q16637" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Survival motor neuron protein</a></td><td headers="hd_b_sma.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://alsod.iop.kcl.ac.uk/Als/Overview/gene.aspx?gene_id=SMN2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">alsod/SMN2 genetic mutations</a><br /><a href="http://reseq.biosciencedbc.jp/resequence/GeneDetail.do?targetId=1&#x00026;geneId=EG6607" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALS mutation database (SMN2)</a><br /><a href="http://databases.lovd.nl/shared/genes/SMN2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMN2 database</a></td><td headers="hd_b_sma.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SMN2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMN2</a></td><td headers="hd_b_sma.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SMN2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMN2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="sma.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="sma.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Spinal Muscular Atrophy (<a href="/omim/253300,253400,253550,271150,600354,601627,602595,603519" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1352/table/sma.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sma.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/253300" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">253300</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPINAL MUSCULAR ATROPHY, TYPE I; SMA1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/253400" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">253400</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPINAL MUSCULAR ATROPHY, TYPE III; SMA3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/253550" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">253550</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPINAL MUSCULAR ATROPHY, TYPE II; SMA2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/271150" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">271150</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPINAL MUSCULAR ATROPHY, TYPE IV; SMA4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/600354" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">600354</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SURVIVAL OF MOTOR NEURON 1; SMN1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601627" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601627</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SURVIVAL OF MOTOR NEURON 2; SMN2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/602595" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">602595</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GEM-ASSOCIATED PROTEIN 2; GEMIN2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603519" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603519</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SURVIVAL MOTOR NEURON DOMAIN-CONTAINING PROTEIN 1; SMNDC1</td></tr></tbody></table></div></div><div id="sma.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><i>SMN1</i> produces a full-length survival motor neuron protein necessary for lower motor neuron function [<a class="bk_pop" href="#sma.REF.lefebvre.1995.155">Lefebvre et al 1995</a>]. <i>SMN2</i> predominantly produces a survival motor neuron protein that is lacking in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7, a less stable protein. SMA is caused by loss of <i>SMN1</i> because <i>SMN2</i> cannot fully compensate for loss of <i>SMN1-</i>produced protein. However, when the <i>SMN2</i> (dosage) copy number is increased, the small amount of full-length transcript generated by <i>SMN2</i> is often able to produce a milder type II or type III <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><div id="sma.SMN1_and_SMN2"><h4><i>SMN1</i> and <i>SMN2</i></h4><p><b>Gene structure.</b> The SMN region on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 5q12.2-q13.3 is unusually complex, with repetitive sequences, pseudogenes, retrotransposable elements, deletions, and inverted duplications [<a class="bk_pop" href="#sma.REF.biros.1999.1">Biros &#x00026; Forrest 1999</a>]. Unaffected individuals have two genes encoding SMN protein that are arranged in tandem on each chromosome: <i>SMN1</i> (telomeric copy, <a href="/nuccore/NM_000344.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000344.3</a>) and <i>SMN2</i> (centromeric copy, <a href="/entrez/viewer.fcgi?val=NM_017411.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_017411.3</a>).</p><ul><li class="half_rhythm"><div>Other terms that have been used to identify <i>SMN1</i>: telSMN, SMNt (t for telomeric), SMNT</div></li><li class="half_rhythm"><div>Other terms that have been used to identify <i>SMN2</i>: cenSMN, SMNc (c for centromeric), BCD541, SMNC</div></li></ul><p><i>SMN1</i> and <i>SMN2</i> each comprise nine exons and differ only in eight nucleotides (5 <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a>; 3 exonic, 1 each located within exons 6, 7, and 8) [<a class="bk_pop" href="#sma.REF.biros.1999.1">Biros &#x00026; Forrest 1999</a>]. <i>SMN1</i> and <i>SMN2</i> share more than 99% nucleotide identity, and both are capable of encoding a 294-amino acid RNA-binding protein, SMN, which is required for efficient assembly of snRNP complexes.</p><p>For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1352/#sma.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Loss of <i>SMN1</i> causes SMA. Individuals with SMA are either <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of at least <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 of <i>SMN1</i> or are <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for such a deletion along with an intragenic <i>SMN1</i> <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Exon 7 of <i>SMN1</i> is undetectable in more than 95% of individuals with SMA irrespective of the clinical subtype of SMA, either as a result of homozygous deletions or <a class="def" href="/books/n/gene/glossary/def-item/gene-conversion/">gene conversion</a> of <i>SMN1</i> sequence into <i>SMN2</i> sequences (possible because of their high nucleotide identity).</p><div id="sma.T.smn2_variants_discussed_in_this_ge" class="table"><h3><span class="label">Table 9. </span></h3><div class="caption"><p><i>SMN2</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1352/table/sma.T.smn2_variants_discussed_in_this_ge/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__sma.T.smn2_variants_discussed_in_this_ge_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_sma.T.smn2_variants_discussed_in_this_ge_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_sma.T.smn2_variants_discussed_in_this_ge_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_sma.T.smn2_variants_discussed_in_this_ge_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_sma.T.smn2_variants_discussed_in_this_ge_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.859G&#x0003e;C</td><td headers="hd_h_sma.T.smn2_variants_discussed_in_this_ge_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly287Arg</td><td headers="hd_h_sma.T.smn2_variants_discussed_in_this_ge_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NM_017411.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_017411<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_059107.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_059107<wbr style="display:inline-block"></wbr>​.1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> SMN is localized to novel nuclear structures called "gems"; gems appear similar to (and possibly interact with) coiled bodies, which are thought to play a role in the processing and metabolism of small nuclear RNAs [<a class="bk_pop" href="#sma.REF.liu.1996.3555">Liu &#x00026; Dreyfuss 1996</a>]. Evidence supports a role for SMN protein in snRNP (small nuclear ribonuclear protein) biogenesis and function [<a class="bk_pop" href="#sma.REF.fischer.1997.1023">Fischer et al 1997</a>, <a class="bk_pop" href="#sma.REF.liu.1997.1013">Liu et al 1997</a>, <a class="bk_pop" href="#sma.REF.pellizzoni.1998.615">Pellizzoni et al 1998</a>]. SnRNPs and possibly other <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> components require regeneration from inactivated to activated functional forms. SMN is required for reassembly and regeneration of these splicing components [<a class="bk_pop" href="#sma.REF.pellizzoni.1998.615">Pellizzoni et al 1998</a>]. SMN accomplishes this in a modular way, bringing together several RNA-binding proteins with several RNAs, facilitating the assembly of specific proteins on the target RNAs.</p><p>The SMN protein has also been reported to influence other cellular activities such as apoptosis and translational regulation [<a class="bk_pop" href="#sma.REF.strasswimmer.1999.1219">Strasswimmer et al 1999</a>, <a class="bk_pop" href="#sma.REF.lefebvre.2002.1017">Lefebvre et al 2002</a>, <a class="bk_pop" href="#sma.REF.vyas.2002.2751">Vyas et al 2002</a>]. SMN modulates apoptosis by blocking the activation of several caspases and other key regulators of cell survival [<a class="bk_pop" href="#sma.REF.anderton.2013.821">Anderton et al 2013</a>]. SMN regulates translation by associating with polysomes, resulting in repression of translation [<a class="bk_pop" href="#sma.REF.sanchez.2013.668">Sanchez et al 2013</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> SMA may be the result of a genetic defect in the biogenesis and trafficking of the spliceosomal snRNP complexes. Mutated SMN, such as that found in individuals with SMA, lacks the <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>-regeneration activity of wild type SMN. Reduced SMN lowers the capacity of cells to assemble the snRNPs, which leads to altered levels of spliceosomal components and defects in splicing, and impaired capacity to produce specific mRNAs and their encoded proteins that are necessary for cellular growth and function. It remains unclear how a defect of splicing results in a motor neuron-specific disorder [<a class="bk_pop" href="#sma.REF.workman.2012.93">Workman et al 2012</a>].</p></div></div></div><div id="sma.References"><h2 id="_sma_References_">References</h2><div id="sma.Published_Guidelines__Consensus_Stat"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="sma.REF.finkel.2018.197">Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Qian Y, Sejersen T, et al.  Diagnosis and management of spinal muscular atrophy: part 2: pulmonary acute care; medications, supplements and immunizations; other organ systems; and ethics. <span><span class="ref-journal">Neuromuscul Disord. </span>2018;<span class="ref-vol">28</span>:197–207.</span> [<a href="/pubmed/29305137" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29305137</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.glascock.2018.145">Glascock J, Sampson J, Haidet-Phillips A, Connolly A, Darras B, Day J, Finkel R, Howell RR, Klinger K, Kuntz N, Prior T, Shieh PB, Crawford TO, Kerr D, Jarecki J. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. <span><span class="ref-journal">J Neuromuscul Dis. </span>2018;<span class="ref-vol">5</span>:145–58.</span> [<a href="/pmc/articles/PMC6004919/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6004919</span></a>] [<a href="/pubmed/29614695" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29614695</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.mercuri.2018.103">Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S, Qian Y, Sejersen T, et al.  Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. <span><span class="ref-journal">Neuromuscul Disord. </span>2018;<span class="ref-vol">28</span>:103–115.</span> [<a href="/pubmed/29290580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29290580</span></a>]</div></li></ul></div><div id="sma.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="sma.REF.anderton.2013.821">Anderton RS, Meloni BP, Mastaglia FL, Boulos S. Spinal muscular atrophy and the antiapoptotic role of survival of motor neuron. <span><span class="ref-journal">Mol Neurobiol. </span>2013;<span class="ref-vol">47</span>:821–32.</span> [<a href="/pubmed/23315303" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23315303</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.andrews.2018.729">Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, Wolff AA, Malik FI. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. <span><span class="ref-journal">Muscle Nerve. </span>2018;<span class="ref-vol">57</span>:729–34.</span> [<a href="/pmc/articles/PMC6681065/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6681065</span></a>] [<a href="/pubmed/29150952" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29150952</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.anhuf.2003.74">Anhuf D, Eggermann T, Rudnik-Sch&#x000f6;neborn S, Zerres K. Determination of SMN1 and SMN2 copy number using TaqMan technology. <span><span class="ref-journal">Hum Mutat. </span>2003;<span class="ref-vol">22</span>:74–8.</span> [<a href="/pubmed/12815596" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12815596</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.arkblad.2006.830">Arkblad EL, Darin N, Berg K, Kimber E, Brandberg G, Lindberg C, Holmberg E, Tulinius M, Nordling M. Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy. <span><span class="ref-journal">Neuromuscul Disord. </span>2006;<span class="ref-vol">16</span>:830–8.</span> [<a href="/pubmed/17049859" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17049859</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.awater.2012.153">Awater C, Zerres K, Rudnik-Sch&#x000f6;neborn S. Pregnancy course and outcome in women with hereditary neuromuscular disorders: comparison of obstetric risks in 178 patients. <span><span class="ref-journal">Eur J Obstet Gynecol Reprod Biol. </span>2012;<span class="ref-vol">162</span>:153–9.</span> [<a href="/pubmed/22459654" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22459654</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.bach.2007.349">Bach JR. Medical considerations of long-term survival of Werdnig-Hoffmann disease. <span><span class="ref-journal">Am J Phys Med Rehabil. </span>2007;<span class="ref-vol">86</span>:349–55.</span> [<a href="/pubmed/17449979" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17449979</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.biros.1999.1">Biros I, Forrest S. Spinal muscular atrophy: untangling the knot? <span><span class="ref-journal">J Med Genet. </span>1999;<span class="ref-vol">36</span>:1–8.</span> [<a href="/pmc/articles/PMC1762953/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1762953</span></a>] [<a href="/pubmed/9950358" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9950358</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.bowerman.2012.256">Bowerman M, Swoboda KJ, Michalski JP, Wang GS, Reeks C, Beauvais A, Murphy K, Woulfe J, Screaton RA, Scott FW, Kothary R. Glucose metabolism and pancreatic defects in spinal muscular atrophy. <span><span class="ref-journal">Ann Neurol. </span>2012;<span class="ref-vol">72</span>:256–68.</span> [<a href="/pmc/articles/PMC4334584/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4334584</span></a>] [<a href="/pubmed/22926856" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22926856</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.brahe.1995.741">Brahe C, Servidei S, Zappata S, Ricci E, Tonali P, Neri G. Genetic homogeneity between childhood-onset and adult-onset autosomal recessive spinal muscular atrophy. <span><span class="ref-journal">Lancet. </span>1995;<span class="ref-vol">346</span>:741–2.</span> [<a href="/pubmed/7658877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7658877</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.bussaglia.1995.335">Bussaglia E, Clermont O, Tizzano E, Lefebvre S, B&#x000fc;rglen L, Cruaud C, Urtizberea JA, Colomer J, Munnich A, Baiget M, Melki J. A frame-shift deletion in the survival motor neuron gene in Spanish spinal muscular atrophy patients. <span><span class="ref-journal">Nat Genet. </span>1995;<span class="ref-vol">11</span>:335–7.</span> [<a href="/pubmed/7581461" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7581461</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.calucho.2018.208">Calucho M, Bernal S, Al&#x000ed;as L, March F, Vencesl&#x000e1; A, Rodr&#x000ed;guez-&#x000c1;lvarez FJ, Aller E, Fern&#x000e1;ndez RM, Borrego S, Mill&#x000e1;n JM, Hern&#x000e1;ndez-Chico C, Cusc&#x000f3; I, Fuentes-Prior P, Tizzano EF. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. <span><span class="ref-journal">Neuromuscul Disord. </span>2018;<span class="ref-vol">28</span>:208–15.</span> [<a href="/pubmed/29433793" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29433793</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.campbell.1998.37">Campbell L, Daniels RJ, Dubowitz V, Davies KE. Maternal mosaicism for a second mutational event in a type I spinal muscular atrophy family. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">63</span>:37–44.</span> [<a href="/pmc/articles/PMC1377239/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377239</span></a>] [<a href="/pubmed/9634516" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9634516</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.chandran.2011.450">Chandran S, McCarthy J, Noonan K, Mann D, Nemeth B, Guiliani T. Early treatment of scoliosis with growing rods in children with severe spinal muscular atrophy: a preliminary report. <span><span class="ref-journal">J Pediatr Orthop. </span>2011;<span class="ref-vol">31</span>:450–4.</span> [<a href="/pubmed/21572284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21572284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.chatwin.2003.502">Chatwin M, Ross E, Hart N, Nickol AH, Polkey MI, Simonds AK. Cough augmentation with mechanical insufflation/exsufflation in patients with neuromuscular weakness. <span><span class="ref-journal">Eur Respir J. </span>2003;<span class="ref-vol">21</span>:502–8.</span> [<a href="/pubmed/12662009" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12662009</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.chien.2017.124">Chien YH, Chiang SC, Weng WC, Lee NC, Lin CJ, Hsieh WS, Lee WT, Jong YJ, Ko TM, Hwu WL. Presymptomatic diagnosis of spinal muscular atrophy through newborn screening. <span><span class="ref-journal">J Pediatr. </span>2017;<span class="ref-vol">190</span>:124–9.e1.</span> [<a href="/pubmed/28711173" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28711173</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.chng.2003.673">Chng SY, Wong YQ, Hui JH, Wong HK, Ong HT, Goh DY. Pulmonary function and scoliosis in children with spinal muscular atrophy types II and III. <span><span class="ref-journal">J Paediatr Child Health. </span>2003;<span class="ref-vol">39</span>:673–6.</span> [<a href="/pubmed/14629498" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14629498</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.clermont.1995.1712">Clermont O, Burlet P, Lefebvre S, B&#x000fc;rglen L, Munnich A, Melki J. SMN gene deletions in adult-onset spinal muscular atrophy. <span><span class="ref-journal">Lancet. </span>1995;<span class="ref-vol">346</span>:1712–3.</span> [<a href="/pubmed/8551862" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8551862</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.dubowitz.1999.49">Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. <span><span class="ref-journal">Eur J Paediatr Neurol. </span>1999;<span class="ref-vol">3</span>:49–51.</span> [<a href="/pubmed/10700538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10700538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.elsheikh.2017.953">Elsheikh BH, Zhang X, Swoboda KJ, Chelnick S, Reyna SP, Kolb SJ, Kissel JT. Pregnancy and delivery in women with spinal muscular atrophy. <span><span class="ref-journal">Int J Neurosci. </span>2017;<span class="ref-vol">127</span>:953–7.</span> [<a href="/pubmed/28102719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28102719</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.finkel.2014.810">Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, Kang PB, Foley AR, Yang ML, Martens WB, Oskoui M, Glanzman AM, Flickinger J, Montes J, Dunaway S, O'Hagen J, Quigley J, Riley S, Benton M, Ryan PA, Montgomery M, Marra J, Gooch C, De Vivo DC. Observational study of spinal muscular atrophy type I and implications for clinical trials. <span><span class="ref-journal">Neurology. </span>2014;<span class="ref-vol">83</span>:810–7.</span> [<a href="/pmc/articles/PMC4155049/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4155049</span></a>] [<a href="/pubmed/25080519" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25080519</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.finkel.2017.1723">Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC, et al.  Nusinersen versus sham control in infantile-onset spinal muscular atrophy. <span><span class="ref-journal">N Engl J Med. </span>2017;<span class="ref-vol">377</span>:1723–32.</span> [<a href="/pubmed/29091570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29091570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.finkel.2018.197_1">Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Qian Y, Sejersen T, et al.  Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. <span><span class="ref-journal">Neuromuscul Disord. </span>2018;<span class="ref-vol">28</span>:197–207.</span> [<a href="/pubmed/29305137" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29305137</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.fischer.1997.1023">Fischer U, Liu Q, Dreyfuss G. The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. <span><span class="ref-journal">Cell. </span>1997;<span class="ref-vol">90</span>:1023–9.</span> [<a href="/pubmed/9323130" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9323130</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.gidaro.2019.19">Gidaro T, Servais L. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. <span><span class="ref-journal">Dev Med Child Neurol. </span>2019;<span class="ref-vol">61</span>:19–24.</span> [<a href="/pubmed/30221755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30221755</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.glascock.2018.145_1">Glascock J, Sampson J, Haidet-Phillips A, Connolly A, Darras B, Day J, Finkel R, Howell RR, Klinger K, Kuntz N, Prior T, Shieh PB, Crawford TO, Kerr D, Jarecki J. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. <span><span class="ref-journal">J Neuromuscul Dis. </span>2018;<span class="ref-vol">5</span>:145–58.</span> [<a href="/pmc/articles/PMC6004919/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6004919</span></a>] [<a href="/pubmed/29614695" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29614695</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.grychtol.2018.18">Grychtol R, Abel F, Fitzgerald DA. The role of sleep diagnostics and non-invasive ventilation in children with spinal muscular atrophy. <span><span class="ref-journal">Paediatr Respir Rev. </span>2018;<span class="ref-vol">28</span>:18–25.</span> [<a href="/pubmed/30396824" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30396824</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.guenther.2007.808">Guenther UP, Varon R, Schlicke M, Dutrannoy V, Volk A, H&#x000fc;bner C, von Au K, Schuelke M. Clinical and mutational profile in spinal muscular atrophy with respiratory distress (SMARD): defining novel phenotypes through hierarchical cluster analysis. <span><span class="ref-journal">Hum Mutat. </span>2007;<span class="ref-vol">28</span>:808–15.</span> [<a href="/pubmed/17431882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17431882</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.hahnen.1997.821">Hahnen E, Schonling J, Rudnik-Sch&#x000f6;neborn S, Raschke H, Zerres K, Wirth B. Missense mutations in exon 6 of the survival motor neuron gene in patients with spinal muscular atrophy (SMA). <span><span class="ref-journal">Hum Mol Genet. </span>1997;<span class="ref-vol">6</span>:821–5.</span> [<a href="/pubmed/9158159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9158159</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.hoffmann.1892.427">Hoffmann J. Familial spinal muscular atrophy in infancy (article in German). <span><span class="ref-journal">Dtsch Z Nervenheilkd. </span>1892;<span class="ref-vol">3</span>:427–70.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.kelley.1986.734">Kelley RI, Sladky JT. Dicarboxylic aciduria in an infant with spinal muscular atrophy. <span><span class="ref-journal">Ann Neurol. </span>1986;<span class="ref-vol">20</span>:734–6.</span> [<a href="/pubmed/3813501" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3813501</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.kolb.2017.883">Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Iannaccone ST, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AHM, Bartlett A, Kissel JT, et al.  Natural history of infantile-onset spinal muscular atrophy. <span><span class="ref-journal">Ann Neurol. </span>2017;<span class="ref-vol">82</span>:883–91.</span> [<a href="/pmc/articles/PMC5776712/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5776712</span></a>] [<a href="/pubmed/29149772" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29149772</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.kugelberg.1956.500">Kugelberg E, Welander L. Heredofamilial juvenile muscular atrophy simulating muscular dystrophy. <span><span class="ref-journal">AMA Arch Neurol Psychiatry. </span>1956;<span class="ref-vol">75</span>:500–9.</span> [<a href="/pubmed/13312732" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13312732</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.lefebvre.1995.155">Lefebvre S, B&#x000fc;rglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, Le Paslier D, Fr&#x000e9;zal J, Cohen D, Weissenbach J, Munnich A, Melki J. Identification and characterization of a spinal muscular atrophy-determining gene. <span><span class="ref-journal">Cell. </span>1995;<span class="ref-vol">80</span>:155–65.</span> [<a href="/pubmed/7813012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7813012</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.lefebvre.2002.1017">Lefebvre S, Burlet P, Viollet L, Bertrandy S, Huber C, Belser C, Munnich A. A novel association of the SMN protein with two major non-ribosomal nucleolar proteins and its implication in spinal muscular atrophy. <span><span class="ref-journal">Hum Mol Genet. </span>2002;<span class="ref-vol">11</span>:1017–27.</span> [<a href="/pubmed/11978761" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11978761</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.lin.2015.293">Lin CW, Kalb SJ, Yeh WS. Delay in diagnosis of spinal muscular atrophy: a systematic literature review. <span><span class="ref-journal">Pediatr Neurol. </span>2015;<span class="ref-vol">53</span>:293–300.</span> [<a href="/pubmed/26260993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26260993</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.liu.1996.3555">Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. <span><span class="ref-journal">EMBO J. </span>1996;<span class="ref-vol">15</span>:3555–65.</span> [<a href="/pmc/articles/PMC451956/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC451956</span></a>] [<a href="/pubmed/8670859" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8670859</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.liu.1997.1013">Liu Q, Fischer U, Wang F, Dreyfuss G. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. <span><span class="ref-journal">Cell. </span>1997;<span class="ref-vol">90</span>:1013–21.</span> [<a href="/pubmed/9323129" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9323129</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.long.2019.1076">Long KK, O'Shea KM, Khairallah RJ, Howell K, Paushkin S, Chen KS, Cote SM, Webster MT, Stains JP, Treece E, Buckler A, Donovan A. Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. <span><span class="ref-journal">Hum Mol Genet. </span>2019;<span class="ref-vol">28</span>:1076–89.</span> [<a href="/pmc/articles/PMC6423420/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6423420</span></a>] [<a href="/pubmed/30481286" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30481286</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.luo.2014.149">Luo M, Liu L, Peter I, Zhu J, Scott SA, Zhao G, Eversley C, Kornreich R, Desnick RJ, Edelmann L. An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy. <span><span class="ref-journal">Genet Med. </span>2014;<span class="ref-vol">16</span>:149–56.</span> [<a href="/pubmed/23788250" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23788250</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.macleod.1999.65">MacLeod MJ, Taylor JE, Lunt PW, Mathew CG, Robb SA. Prenatal onset spinal muscular atrophy. <span><span class="ref-journal">Eur J Paediatr Neurol. </span>1999;<span class="ref-vol">3</span>:65–72.</span> [<a href="/pubmed/10700541" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10700541</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.malcov.2004.199">Malcov M, Schwartz T, Mei-Raz N, Yosef DB, Amit A, Lessing JB, Shomrat R, Orr-Urtreger A, Yaron Y. Multiplex nested PCR for preimplantation genetic diagnosis of spinal muscular atrophy. <span><span class="ref-journal">Fetal Diagn Ther. </span>2004;<span class="ref-vol">19</span>:199–206.</span> [<a href="/pubmed/14764971" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14764971</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.mcandrew.1997.1411">McAndrew PE, Parsons DW, Simard LR, Rochette C, Ray PN, Mendell JR, Prior TW, Burghes AH. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. <span><span class="ref-journal">Am J Hum Genet. </span>1997;<span class="ref-vol">60</span>:1411–22.</span> [<a href="/pmc/articles/PMC1716150/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1716150</span></a>] [<a href="/pubmed/9199562" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9199562</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.mendell.2017.1713">Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L'Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK. Single-dose gene-replacement therapy for spinal muscular atrophy. <span><span class="ref-journal">N Engl J Med. </span>2017;<span class="ref-vol">377</span>:1713–22.</span> [<a href="/pubmed/29091557" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29091557</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.mercuri.2016.126">Mercuri E, Finkel R, Montes J, Mazzone ES, Sormani MP, Main M, Ramsey D, Mayhew A, Glanzman AM, Dunaway S, Salazar R, Pasternak A, Quigley J, Pane M, Pera MC, Scoto M, Messina S, Sframeli M, Vita GL, D'Amico A, van den Hauwe M, Sivo S, Goemans N, Kaufmann P, Darras BT, Bertini E, Muntoni F, De Vivo DC. Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials. <span><span class="ref-journal">Neuromuscul Disord. </span>2016;<span class="ref-vol">26</span>:126–31.</span> [<a href="/pmc/articles/PMC4762230/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4762230</span></a>] [<a href="/pubmed/26776503" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26776503</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.mercuri.2018.103_1">Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S, Qian Y, Sejersen T, et al.  Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. <span><span class="ref-journal">Neuromuscul Disord. </span>2018;<span class="ref-vol">28</span>:103–15.</span> [<a href="/pubmed/29290580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29290580</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.miske.2004.1406">Miske LJ, Hickey EM, Kolb SM, Weiner DJ, Panitch HB. Use of the mechanical in-exsufflator in pediatric patients with neuromuscular disease and impaired cough. <span><span class="ref-journal">Chest. </span>2004;<span class="ref-vol">125</span>:1406–12.</span> [<a href="/pubmed/15078753" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15078753</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.montes.2018.e0199657">Montes J, McDermott MP, Mirek E, Mazzone ES, Main M, Glanzman AM, Duong T, Young SD, Salazar R, Pasternak A, Gee R, De Sanctis R, Coratti G, Forcina N, Fanelli L, Ramsey D, Milev E, Civitello M, Pane M, Pera MC, Scoto M, Day JW, Tennekoon G, Finkel RS, Darras BT, Muntoni F, De Vivo DC, Mercuri E. Ambulatory function in spinal muscular atrophy: age-related patterns of progression. <span><span class="ref-journal">PLoS One. </span>2018;<span class="ref-vol">13</span>:e0199657</span> [<a href="/pmc/articles/PMC6019250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6019250</span></a>] [<a href="/pubmed/29944707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29944707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.moutou.2003.685">Moutou C, Gardes N, Viville S. Duplex PCR for preimplantation genetic diagnosis (PGD) of spinal muscular atrophy. <span><span class="ref-journal">Prenat Diagn. </span>2003;<span class="ref-vol">23</span>:685–9.</span> [<a href="/pubmed/12913876" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12913876</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.norwood.2012.183">Norwood F, Rudnik-Sch&#x000f6;neborn S. 179th ENMC international workshop: pregnancy in women with neuromuscular disorders 5-7 November 2010, Naarden, The Netherlands. <span><span class="ref-journal">Neuromuscul Disord. </span>2012;<span class="ref-vol">22</span>:183–90.</span> [<a href="/pubmed/21689937" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21689937</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.ogino.2002.477">Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). <span><span class="ref-journal">Hum Genet. </span>2002;<span class="ref-vol">111</span>:477–500.</span> [<a href="/pubmed/12436240" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12436240</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.oprea.2008.524">Oprea GE, Krober S, Mcwhorter ML, Rossoll W, Muller S, Krawczak S, Bassell GJ, Beattie CE, Wirth B. Plastin 3 is a protective modifier os autosomal recessive spinal muscular atrophy. <span><span class="ref-journal">Science. </span>2008;<span class="ref-vol">320</span>:524–7.</span> [<a href="/pmc/articles/PMC4908855/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4908855</span></a>] [<a href="/pubmed/18440926" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18440926</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.oskoui.2007.1931">Oskoui M, Levy G, Garland CJ, Gray JM, O'Hagen J, De Vivo DC, Kaufmann P. The changing natural history of spinal muscular atrophy type 1. <span><span class="ref-journal">Neurology. </span>2007;<span class="ref-vol">69</span>:1931–6.</span> [<a href="/pubmed/17998484" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17998484</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.parsons.1998.1712">Parsons DW, McAndrew PE, Iannaccone ST, Mendell JR, Burghes AH, Prior TW. Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">63</span>:1712–23.</span> [<a href="/pmc/articles/PMC1377643/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377643</span></a>] [<a href="/pubmed/9837824" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9837824</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.parsons.1996.1727">Parsons DW, McAndrew PE, Monani UR, Mendell JR, Burghes AH, Prior TW. An 11 base pair duplication in exon 6 of the SMN gene produces a type I spinal muscular atrophy (SMA) phenotype: further evidence for SMN as the primary SMA-determining gene. <span><span class="ref-journal">Hum Mol Genet. </span>1996;<span class="ref-vol">5</span>:1727–32.</span> [<a href="/pubmed/8922999" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8922999</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.pellizzoni.1998.615">Pellizzoni L, Kataoka N, Charroux B, Dreyfuss G. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. <span><span class="ref-journal">Cell. </span>1998;<span class="ref-vol">95</span>:615–24.</span> [<a href="/pubmed/9845364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9845364</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.petrone.2007.216">Petrone A, Pavone M, Testa MB, Petreschi F, Bertini E, Cutrera R. Noninvasive ventilation in children with spinal muscular atrophy types 1 and 2. <span><span class="ref-journal">Am J Phys Med Rehabil. </span>2007;<span class="ref-vol">86</span>:216–21.</span> [<a href="/pubmed/17314706" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17314706</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.prior.2009.408">Prior TW, Krainer AR, Hua Y, Swoboda KJ, Snyder PC, Bridgeman SJ, Burghes AH, Kissel JT. A positive modifier of spinal muscular atrophy in the SMN2 gene. <span><span class="ref-journal">Am J Hum Genet. </span>2009;<span class="ref-vol">85</span>:408–13.</span> [<a href="/pmc/articles/PMC2771537/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2771537</span></a>] [<a href="/pubmed/19716110" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19716110</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.prior.2004.307">Prior TW, Swoboda KJ, Scott HD, Hejmanowski AQ. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. <span><span class="ref-journal">Am J Med Genet A. </span>2004;<span class="ref-vol">130A</span>:307–10.</span> [<a href="/pmc/articles/PMC4349519/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4349519</span></a>] [<a href="/pubmed/15378550" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15378550</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.rigo.2014.46">Rigo F, Chun SJ, Norris DA, Hung G, Lee S, Matson J, Fey RA, Gaus H, Hua Y, Grundy JS, Krainer AR, Henry SP, Bennett CF. Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. <span><span class="ref-journal">J Pharmacol Exp Ther. </span>2014;<span class="ref-vol">350</span>:46–55.</span> [<a href="/pmc/articles/PMC4056267/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4056267</span></a>] [<a href="/pubmed/24784568" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24784568</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.sanchez.2013.668">Sanchez G, Dury AY, Murray LM, Biondi O, Tadesse H, El Fatimy R, Kothary R, Charbonnier F, Khandjian EW, Cote J. A novel function for the survival motorneuron protein as a translational regulator. <span><span class="ref-journal">Hum mol Genet. </span>2013;<span class="ref-vol">22</span>:668–84.</span> [<a href="/pubmed/23136128" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23136128</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.scarciolla.2006.269">Scarciolla O, Stuppia L, De Angelis MV, Murru S, Palka C, Giuliani R, Pace M, Di Muzio A, Torrente I, Morella A, Grammatico P, Giacanelli M, Rosatelli MC, Uncini A, Dallapiccola B. Spinal muscular atrophy genotyping by gene dosage using multiple ligation-dependent probe amplification. <span><span class="ref-journal">Neurogenetics. </span>2006;<span class="ref-vol">7</span>:269–76.</span> [<a href="/pubmed/16865356" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16865356</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.shorrock.2018.293">Shorrock HK, Gillingwater TH, Groen EJN. Overview of current drugs and molecules in development for spinal muscular atrophy therapy. <span><span class="ref-journal">Drugs. </span>2018;<span class="ref-vol">78</span>:293–305.</span> [<a href="/pmc/articles/PMC5829132/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5829132</span></a>] [<a href="/pubmed/29380287" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29380287</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.sporer.2003.10">Sporer SM, Smith BG. Hip dislocation in patients with spinal muscular atrophy. <span><span class="ref-journal">J Pediatr Orthop. </span>2003;<span class="ref-vol">23</span>:10–4.</span> [<a href="/pubmed/12499935" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12499935</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.strasswimmer.1999.1219">Strasswimmer J, Lorson CL, Breiding DE, Chen JJ, Le T, Burghes AH, Androphy EJ. Identification of survival motor neuron as a transcriptional activator-binding protein. <span><span class="ref-journal">Hum Mol Genet. </span>1999;<span class="ref-vol">8</span>:1219–26.</span> [<a href="/pubmed/10369867" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10369867</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.sugarman.2012.27">Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, Flynn K, Hendrickson BC, Scholl T, Sirko-Osadsa DA, Allitto BA. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of &#x0003e;72,400 specimens. <span><span class="ref-journal">Eur J Hum Genet. </span>2012;<span class="ref-vol">20</span>:27–32.</span> [<a href="/pmc/articles/PMC3234503/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3234503</span></a>] [<a href="/pubmed/21811307" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21811307</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.talbot.1997.497">Talbot K, Ponting CP, Theodosiou AM, Rodrigues NR, Surtees R, Mountford R, Davies KE. Missense mutation clustering in the survival motor neuron gene: a role for a conserved tyrosine and glycine rich region of the protein in RNA metabolism? <span><span class="ref-journal">Hum Mol Genet. </span>1997;<span class="ref-vol">6</span>:497–500.</span> [<a href="/pubmed/9147655" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9147655</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.tizzano.2017.883">Tizzano EF, Finkel RS. Spinal muscular atrophy: a changing phenotype beyond the clinical trials. <span><span class="ref-journal">Neuromuscul Disord. </span>2017;<span class="ref-vol">27</span>:883–9.</span> [<a href="/pubmed/28757001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28757001</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.verhaart.2017.124">Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, Cook SF, Lochm&#x000fc;ller H. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2017;<span class="ref-vol">12</span>:124.</span> [<a href="/pmc/articles/PMC5496354/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5496354</span></a>] [<a href="/pubmed/28676062" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28676062</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.vyas.2002.2751">Vyas S, Bechade C, Riveau B, Downward J, Triller A. Involvement of survival motor neuron (SMN) protein in cell death. <span><span class="ref-journal">Hum Mol Genet. </span>2002;<span class="ref-vol">11</span>:2751–64.</span> [<a href="/pubmed/12374765" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12374765</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.wadman.2017.365">Wadman RI, Stam M, Gijzen M, Lemmink HH, Snoeck IN, Wijngaarde CA, Braun KP, Schoenmakers MA, van den Berg LH, Dooijes D, van der Pol WL. Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0-4. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2017;<span class="ref-vol">88</span>:365–7.</span> [<a href="/pubmed/28108522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28108522</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.wang.2007.1027">Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, Aloysius A, Morrison L, Main M, Crawford TO, Trela A., Participants of the International Conference on SMA Standard of Care.  Consensus statement for standard of care in spinal muscular atrophy. <span><span class="ref-journal">J Child Neurol. </span>2007;<span class="ref-vol">22</span>:1027–49.</span> [<a href="/pubmed/17761659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17761659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.werdnig.1971.276">Werdnig G. Two early infantile hereditary cases of progressive muscular atrophy simulating dystrophy, but on a neural basis. 1891. <span><span class="ref-journal">Arch Neurol. </span>1971;<span class="ref-vol">25</span>:276–8.</span> [<a href="/pubmed/4952838" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4952838</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.wirth.2000.228">Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy. <span><span class="ref-journal">Hum Mutat. </span>2000;<span class="ref-vol">15</span>:228–37.</span> [<a href="/pubmed/10679938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10679938</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.wirth.1997.1102">Wirth B, Schmidt T, Hahnen E, Rudnik-Sch&#x000f6;neborn S, Krawczak M, Muller-Myhsok B, Schonling J, Zerres K. De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling. <span><span class="ref-journal">Am J Hum Genet. </span>1997;<span class="ref-vol">61</span>:1102–11.</span> [<a href="/pmc/articles/PMC1716038/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1716038</span></a>] [<a href="/pubmed/9345102" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9345102</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.workman.2012.93">Workman E, Kolb SJ, Battle DJ. Spliceosomal small nuclear ribonucleoprotein biogenesis defects and motor neuron selectivity in spinal muscular atrophy. <span><span class="ref-journal">Brain Res. </span>2012;<span class="ref-vol">1462</span>:93–9.</span> [<a href="/pmc/articles/PMC3448484/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3448484</span></a>] [<a href="/pubmed/22424789" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22424789</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.yoon.2014.1196">Yoon WW, Sedra F, Shah S, Wallis C, Muntoni F, Noordeen H. Improvement of pulmonary function in children with early-onset scoliosis using magnetic growth rods. <span><span class="ref-journal">Spine (Phila Pa 1976). </span>2014;<span class="ref-vol">39</span>:1196–202.</span> [<a href="/pubmed/24825149" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24825149</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="sma.REF.zerres.1997.67">Zerres K, Rudnik-Sch&#x000f6;neborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. <span><span class="ref-journal">J Neurol Sci. </span>1997;<span class="ref-vol">146</span>:67–72.</span> [<a href="/pubmed/9077498" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9077498</span></a>]</div></li></ul></div></div><div id="sma.Chapter_Notes"><h2 id="_sma_Chapter_Notes_">Chapter Notes</h2><div id="sma.Author_History"><h3>Author History</h3><p>Erika Finanger, MD (2016-present)<br />Meganne E Leach, MSN, PNP (2019-present)<br />Thomas W Prior, PhD, FACMG (2000-present)<br />Barry S Russman, MD; Oregon Health and Science University (2000-2016)</p></div><div id="sma.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>14 November 2019 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 December 2016 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>14 November 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>27 January 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 April 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 July 2004 (br) Revision: Management</div></li><li class="half_rhythm"><div>17 October 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>24 February 2000 (me) Review posted live</div></li><li class="half_rhythm"><div>28 February 1999 (br) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1352</span><span class="label">PMID: <a href="/pubmed/20301526" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301526</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/kennedy/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sma-xli/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1352&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1352/?report=reader">PubReader</a></li><li><a href="/books/NBK1352/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1352" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1352" style="display:none" title="Cite this Page"><div class="bk_tt">Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. 2000 Feb 24 [Updated 2019 Nov 14]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1352/pdf/Bookshelf_NBK1352.pdf">PDF version of this page</a> (724K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#sma.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#sma.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#sma.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#sma.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#sma.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#sma.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#sma.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#sma.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#sma.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#sma.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#sma.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#sma.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=57222[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ERGIC1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8487[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">GEMIN2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6607[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SMN2</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=10285[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SMNDC1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6606[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SMN1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1480904" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1480904" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1480904" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1480904" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29595935" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ASAH1</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ASAH1</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dyment DA, Bennett SAL, Medin JA, Levade T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301468" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Muscular Dystrophy Overview</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Muscular Dystrophy Overview<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sparks SE, Quijano-Roy S, Harper A, Rutkowski A, Gordon E, Hoffman EP, Pegoraro E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301739" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinal Muscular Atrophy, X-Linked Infantile</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spinal Muscular Atrophy, X-Linked Infantile<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Baumbach-Reardon L, Sacharow SJ, Ahearn ME. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301503" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Disorders of Intracellular Cobalamin Metabolism</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Disorders of Intracellular Cobalamin Metabolism<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sloan JL, Carrillo N, Adams D, Venditti CP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24741716" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">RRM2B</i>-Related Mitochondrial Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">RRM2B</i>-Related Mitochondrial Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gorman GS, Taylor RW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301526" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301526" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc8c1875f66d18aafa9aec">Spinal Muscular Atrophy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Spinal Muscular Atrophy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T03:53:45-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE888D43DFC8982100000000013B0090&amp;ncbi_session=CE888D43DFC8C181_0315SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1352%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1352&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1352/&amp;ncbi_pagename=Spinal Muscular Atrophy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE888D43DFC8C181_0315SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>